Title:

Mechanistic and Antigenic Boundaries of *Henipavirus* and *Parahenipavirus* Glycoproteins

Authors:

Aaron J. May[1,2,*], Muralikrishna Lella[1,#], Jared Lindenberger[1,#], Alex Berkman[1,#], Ujjwal Kumar[1], Moumita Dutta[1], Maggie Barr[1], Rob Parks[1], Xiaozhi Lu[1], Madison Berry[1], Amanda Newman[1], Xiao Huang[1], Arpita Mrigwani[1], Kijun Song[1,2], Victor Ilevbare[1], Salam Sammour[1], Chan Soo Park[1], Radha Devkota Adhikari[1], Priyanka Devkota[1], Katarzyna Janowska[1], Yanshun Liu[1], Garrett Scapellato[1], Taylor N. Spence[1], Katayoun Mansouri[1], Kevin Wiehe[1,3], Robert J Edwards[1,3], Kevin O. Saunders[1,4,5], Barton F. Haynes[1,3,4], Priyamvada Acharya[1,2,5,*,$]

Affiliations:

[1] Duke University, Duke Human Vaccine Institute, Durham NC 27710, USA

[2] Duke University, Department of Biochemistry, Durham NC 27710, USA

[3] Duke University, Department of Medicine, Durham, NC 27710, USA

[4] Duke University, Department of Integrative Immunology, Durham NC 27710, USA

[5] Duke University, Department of Surgery, Durham NC 27710, USA

[$]Lead contact

#These authors contributed equally

[*]Correspondence: aaron.may@duke.edu (A.M.), priyamvada.acharya@duke.edu (P.A.)

Summary:

Henipaviruses, a genus within the *Paramyxoviridae* family, include the highly virulent Nipah and Hendra viruses that cause reoccurring outbreaks of deadly disease. Recent discoveries of several new *Paramyxoviridae* species, including the zoonotic Langya virus, have revealed much higher antigenic diversity than currently characterized and prompted the reorganization of these viruses into the *Henipavirus* and *Parahenipavirus* genera. Here, to explore the limits of structural and antigenic variation in both genera, collectively referred to here as HNVs, we constructed an expanded, antigenically diverse panel of HNV fusion and attachment glycoproteins from 56 unique HNV strains that better reflects global HNV diversity. We expressed and purified the fusion protein ectodomains and the attachment protein head domains and studied their biochemical, biophysical and structural properties. We performed immunization experiments in mice leading to the elicitation of antibodies reactive to multiple HNV fusion proteins. Cryo-electron microscopy structures of diverse fusion proteins elucidated molecular determinants of differential pre-fusion state metastability and higher order contacts. A crystal structure of the Gamak virus attachment head domain revealed an additional domain appended to the conserved 6-bladed, β-propeller fold. Taken together, these studies expand the known structural and antigenic limits of the HNVs, reveal new cross-reactive epitopes within both genera and provide foundational data for the development of broadly reactive countermeasures.

Introduction

Henipaviruses (HNVs) are a genus of single-stranded RNA (ssRNA) viruses that includes the highly virulent Nipah virus (NiV) responsible for reoccurring outbreaks of deadly disease. The *Henipavirus* genus is a part of the *Paramyxoviridae* family, and therefore related to other notable human pathogens such as the parainfluenza viruses, measles, and mumps [1]. The combined possibility within the family for both rapid transmission, as with measles, and high lethality, as with NiV, further highlights pandemic risk and necessitates urgent research to establish preparedness that will enable a rapid and effective response to a future emergent threat. For HNVs specifically, their identification in diverse animal reservoirs in different geographical locations, their high risk of zoonotic transmission, and current lack of approved vaccines or therapies to treat HNV infection in humans highlights the high risk and pandemic potential of this genus.

HNVs have been studied since the discovery of Hendra (HeV) and Nipah viruses in 1994 and 1998, respectively [2-4]. Additional members of the genus have been identified since then, but it was not until 2022 with the discovery of Langya virus (LayV) that another species with pathogenicity in humans was confirmed [5]. Like HeV and NiV, LayV was of zoonotic origin. However, unlike HeV, NiV, and most of the other known HNVs at the time, LayV was found to have likely originated from a shrew reservoir, rather than from fruit bats. Several concurrent studies identified more shrew-borne HNVs over a wide geographic range, indicating the existence of a largely uncharacterized clade within the Henipavirus genus [6-8]. Among these studies were some untargeted surveillance efforts, revealing new HNV sequences among dozens of other sequences across multiple virus families [9]. While the newly discovered shrew-borne species had initially been classified as members of the *Henipavirus* genus, they have recently been reclassified into the *Parahenipavirus* genus [10]. In this study, we use the abbreviation HNV to refer collectively to species of both genera.

The HNV attachment (G) and fusion (F) surface glycoproteins together facilitate virus entry into host cells, with G responsible for receptor binding and F mediating viral and host membrane fusion. During this process, both G and F undergo important conformational changes, including destabilization of the prefusion conformation of F by G. The specifics of these conformational steps, including how G destabilizes the pre-fusion F conformation or "triggers" its pre-fusion to post-fusion transition remain elusive. Although a class I fusion protein [11], the HNV-F protein, along with all *Paramyxoviridae* F proteins, differs from the canonical class I fusion mechanism in that there is a separation of the receptor attachment function into a separate protein [12]. Whereas other viral fusion proteins proceed through the fusion conversion process by repositioning or removal of their attachment subunits, HNV-F proteins retain inherent metastability through F protein architecture alone.

In addition to their role in virus entry, F and G are the sole targets for neutralizing
antibodies on the surface of HNVs, and thus are important from the perspective of preventative
and therapeutic countermeasure development [13]. The antigenicity of the F and G proteins, outside
those of the more well-studied Nipah and Hendra viruses, and the possibility of cross-reactivity
across the genus remains largely unexplored. While there are several known monoclonal
antibodies (mAbs) that are able to neutralize both NiV and HeV [14-18], so far none of these have
been found to have any reactivity with LayV [19,20]. Of the few mAbs known to bind to LayV,
some have been noted to be cross-reactive with Mojiang virus (MojV), but not to NiV or HeV [20].
Whether there are any broadly reactive anti-HNV antibodies or where the limits of cross-
reactivity are within the genera considering newly-discovered species remains unknown. To
address these genus-wide mechanistic and antigenic questions, we assembled a curated set of
HNV G and F sequences that samples the diversity of the genus as broadly as possible. We
purified and characterized these proteins biochemically, biophysically, and structurally. By
vaccinating mice with diverse HNV F proteins we elicited and isolated new antibodies with
broad reactivity within the *Parahenipavirus* genus. We identified species with F proteins that
demonstrate heightened pre-fusion stability; by translating structural features from these
proteins, we stabilized the pre-fusion conformation of F proteins across the HNV genera. For the
G protein, we characterized the binding of a G head domain panel to Ephrin B2 and B3, the
known receptors for NiV and HeV, and to a panel of known anti-NiV antibodies. Additionally,
we visualized a novel domain of a *Parahenivpavirus* G protein. Taken together, our findings in
this study begin to distinguish antigenic groupings within recently discovered HNVs, clarify
receptor binding differences in newly discovered species and antigenic relationships within the
HNV genera, visualize new structural features in the F and G proteins, and provide insights for
translateable pre-fusion stabilization techniques.
123
Identification and Classification of HNV Species
To begin categorizing this diverse set of HNV strains, we identified as many unique
HNV G and F ectodomains as could be found and assessed the phylogeny of these sequences.
We used NCBI BLAST [21] to search for unique HNV-like sequences related to the input
sequence, NC_002728 [22]. We also carried out an extensive literature search to include other
sequences that may not have been discoverable through BLAST, such as Gamak virus [6]. Next,
we narrowed the list to include only sequences from mostly complete genomes, leaving out those
where only partial DNA sequences of G or F proteins were available. Almost all the strains that
were selected had genome lengths close to the canonical 18.2 kbp for HNVs [23], with some of the
species selected having slightly longer genomes reported. No sequence in our panel had a
deposited genome shorter than 11.2 kbp. The several sequences that were shorter than the rest
were either Nipah-Malaysia or Hendra strains that we included since they have been well-
characterized in the literature.
137

Next, Clustal Omega [24] was used to align the G and F amino acid sequences. To generate
the soluble ectodomain constructs, we truncated the sequences, using trends in the sequence
alignments to decide on exact truncation points between species. All HNV-F ectodomains were
of similar length, allowing all to be truncated at the C-terminal end of the ectodomain at the site
equivalent to Nipah virus residue 488, consistent with previous F ectodomain constructs [19]
(**Supplemental Data 1, Supplemental Table 1**). For the G proteins, the domain boundaries did
not align as consistently across species as they do with the overall less variable F protein, though
the N-terminal portion of the sequence up to the end of the transmembrane domain was relatively
consistent across all species, allowing for the truncation position for the ectodomain to be set at
the analogous site to Nipah virus residue 71. While the full G ectodomain and its elusive fusion
promotion mechanism is an important area for research, in this study we focus on the G head
domain that harbors the receptor binding site and is targeted by a myriad of neutralizing
antibodies [14,16,25,26]. Therefore, while our sequence and phylogenetic analysis considers the whole
genome or full G amino acid sequence, only the head domains of G proteins were purified. For
these head domains, sequence variability resulted in the transition between the neck domain and
head domain being less clear from sequence (**Supplemental Data 2**). In classical *Henipavirus*
sequences, there are frequent glycine and proline residues leading up to a conserved cysteine in
the head domain. The Parahenipaviruses also contain a proline-rich region before the head
domain, with as many as five consecutive prolines in some sequences. This proline-rich region is
often followed in Parahenipaviruses by many aspartic and glutamic acid residues. Ultimately, for
each strain we sought to select the site analogous to Nipah virus residue 177 as a suitable start
point based on sequence analysis and available structural data for Nipah and Langya G proteins
[14,27] (**Supplemental Data 2, Supplemental Table 1**). After removing redundant sequences
where differences were noted only in the signal sequence, transmembrane domains, cytosolic
domains, or other regions not included in the final F ectodomain or G head domain constructs,
the panel was assembled into a phylogenetic tree based on complete genomes (**Figure 1**). From
this list, a subset of unique F ectodomains and G head domains was purified that would broadly
sample the diversity of species in the phylogenetic tree, resulting in 35 purified F ectodomains
and 32 purified G head domains. A listing of the sequence source for each purified protein can be
found in **Supplemental Table 1** and exact amino acid sequences in **Supplemental Data 1-2.**
168
The International Committee on Taxonomy of Viruses (ICTV) has recently updated
terminology related to the Henipaviruses, establishing the *Henipavirus* and *Parahenipavirus*
genera, and specifying select species within these groups [10]. Our effort to compare the properties
of dozens of unique F and G sequences required finer granularity than the species level, and as a
result, for this study we adopted an abbreviation and numbering scheme to aid in distinguishing
specific sequences. The basis for this terminology is expanded upon in **Supplemental Note 1**
and the corresponding accession code and current ICTV name for each sequence is listed in
Supplemental Table 1.
177

For F proteins, the sequence identity relative to NiV-M1-F is high for both NiV and HeV
strains, with all NiV sequences over 98% and HeV strains over 97% (**Supplemental Figure 1**).
The sequence identity of most non-NiV/HeV strains to NiV-M1-F is ~40%, with sequence
similarity around 55-60%, revealing that the F protein is relatively well conserved across genera.
A phylogenetic tree of HNV-F proteins based on amino acid sequences was overall similar to the
whole genome tree with several small differences. Specifically, the distinction between NiV-C-F
and NiV-M strains is more apparent in the F-based phylogenetic tree, the F proteins of SHNV3
and SHNV11 appear to be very closely related, and AngV-F appeared distinct from all other
HNV strains, rather than part of the bat clade as seen through full-genome phylogeny
(**Supplemental Figure 2, Top**).
188
Compared to F proteins, HNV-G proteins demonstrate much greater sequence variability.
Sequence identity values are only ~78% between NiV and HeV, and drop to below 20% for
Parahenipavirus G proteins, compared to NiV-M1-G (**Supplemental Figure 1B**). The sequence
similarity scores are also rather low, with most Parahenipavirus strains at around 35% similarity
to NiV (**Supplemental Figure 1B**). When considering amino acid-based phylogeny, the
relationships between strains remain similar as we had observed for the F ectodomains
(**Supplemental Figure 2, Top**). One notable difference is that SHNV3-G and SHNV11-G, as
with their F counterparts, appear more closely related than their full genome would suggest
(**Supplemental Figure 2, Bottom**). Overall, the limited sequence similarity observed for the G
head domains suggests that there could be greater antigenic, structural, and mechanistic
differences between different HNV-G proteins than among F proteins.
200
Preparation of Diverse HNV-F Ectodomains
We expressed 35 HNV-F ectodomains constructs that encoded residues 1 to the
equivalent of 488 in NiV, followed by a foldon trimerization domain [28] and a C-terminal Twin
Strep tag. For all constructs, the putative natural cleavage site that allows processing from the F_0
precursor to the fusion-competent F_1/F_2 complex was retained. Following expression of the
protein through transient transfection in HEK 293F cells and purification using their C-terminal
Strep affinity tags followed by size exclusion chromatography (SEC), we obtained variable
yields of F proteins, with some constructs expressing over 2 mg/L and others less than 0.1 mg/L
(**Supplemental Figure 1**). For eight F proteins, the yields were too low to perform any
downstream studies. We found that yields could vary dramatically between strains that only
differed by a few amino acids. For example, NiV-B1.1-F and NiV-B1.2-F differ by only three
residues in the ectodomain, but while NiV-B1.2-F produced ~1 mg/L, NiV-B1.1-F had no yield
across two purification attempts.
214
HNV-F ectodomains typically eluted from SEC with three peaks, one that eluted
immediately after the column void volume, a broad "middle peak," and the "main peak" that
corresponds to the molecular weight of an F trimer eluting last (**Figure 2A, Supplemental**

Figure 3), with the ratio of the peaks differing from strain to strain (**Supplemental Figure 1**).
For some strains, a shoulder was observed for the middle peak, suggesting multiple sized
components eluting within this peak. The SDS-PAGE profile of the middle peak fractions
showed a major band at the molecular weight expected for the trimeric ectodomain unit,
indicating that the presence of the higher molecular weight peak was not a result of any covalent
linkage or differential glycosylation that would change the molecular weight enough to be
distinguishable on SDS-PAGE (**Supplemental Figure 4**). This conclusion is supported by mass
photometry analysis, where both the middle and main peaks, individually or mixed together,
generated an essentially identical molecular weight profile, with each being dominated by the
expected molecular weight of the trimer, and both showing a very small presence of species ~2-3
times the mass of the trimer (**Figure 2A, Insert)**). SDS-PAGE also indicated that all F proteins
are being expressed in their F_0 state, without any proteolytic processing to F_1/F_2 (**Supplemental
Figure 4).** Negative stain electron microscopy (NSEM) of each middle or main peak reveals
comparable sets of two-dimensional class averages. The typical pre- and postfusion shapes
identified previously [19] can be seen throughout the panel for both middle and main peak
components (**Supplemental Figure 5**). Taken together, these data suggest that the middle peak
is composed of transient, non-covalently associated F ectodomain trimers, which are reminiscent
of previous studies of *Paramyxoviridae* F proteins where oligomeric states were reported for the
F protein [25,29,30]. In summary, though the F protein expression yields varied greatly, similar
profiles were observed through SEC, SDS-PAGE, and NSEM analysis across all HNV species
tested.
239
240   ***Antigenicity of HNV-F Ectodomains***
241   We next characterized the antigenicity of the F ectodomain panel. Since many new HNV
species have been recently identified and given the limited availability of antibodies that react
with LayV and other newly categorized members of our panel, we sought to identify antibodies
of novel specificities by vaccinating mice with HNV-F antigens (**Figure 2B)**. One group was
given four injections of the LayV-C1-F ectodomain, and for two others, the fourth injection of
LayV-C1-F was replaced with NiV-F protein constructs, either the wild-type NiV-M1-F, or
NiVop08, a pre-fusion stabilized NiV-F construct [31]. By boosting with NiV-F constructs, we
sought to elicit broadly reactive antibodies. Using hybridoma fusion technology [32], we identified
two murine IgG1 antibodies, named 1C8 and 22F5, both from group 2, with reactivity to LayV-
1-F. An additional vaccination series, using the same antigens with a similar timeline, led to the
isolation of an additional four murine antibodies, all from group 2, named 9A9, 8C7, 20G7, and
8D4 (**Supplemental Figure 6**).
253
254   The binding of antibodies elicited in our immunization experiments, as well as previously
identified anti-NiV or anti-LayV antibodies, to our panel of HNV-F ectodomains was assessed
by enzyme-linked immunosorbent assay (ELISA), surface plasmon resonance (SPR), or Bio-
layer interferometry (BLI) [20,33] (**Figure 2C, Supplemental Figures 7-9)**. 1H1 and 4B8,

previously identified anti-NiV-F antibodies, displayed broad reactivity to all NiV and HeV
strains, but extremely limited reactivity to all other species. A panel of previously characterized
mouse anti-NiV-F Fabs broadly reacted to nearly all NiV and HeV antigens, as expected. 4G5,
previously identified as an anti-LayV-F and MojV-F antibody that binds both the pre- and post-
fusion conformations at an epitope involving the HRA and HRB regions, strongly bound not
only to LayV-F and MojV-F, but also to SHNV5-1-F and SHNV5-2-F, thus indicating that
antibodies targeting the 4G5 epitope have greater breadth than was previously known (**Figure
2C, Supplemental Figure 7-8**).

Of the antibodies isolated from the immunization studies, 8C7, 20G7, and 9A9 bound
only to NiV-F ectodomains. 1C8, 22F5, and 8D4 demonstrated strong reactivity not only to
LayV-F proteins, but also to MojV-F and both SHNV5 strains. Moreover, 22F5, which generated
stronger binding signals than 1C8, bound to SHNV2-F as well (**Figure 2C**). 8D4 demonstrated
the broadest binding profile, with binding detected to F proteins from each of GakV-1, GakV-2,
NinV, SHNV1, SHNV2, and SHNV3 (**Supplemental Figure 9C).** Considering the phylogenetic
relationships of these strains (**Figure 1**), it appears that 8D4's reactivity covers nearly the
entirety of the known Parahenipaviruses. However, 8D4 demonstrated sharply reduced binding
to pre-fusion stabilized F constructs, indicating that it specifically bound to the post-fusion F
conformation (**Supplemental Figure 9C).** Since there are very few well-characterized antibodies
that have been described for Parahenipaviruses, we selected 22F5 for detailed characterization,
given its combination of a broad cross-reactivity profile and ability to bind pre-fusion F proteins.

To assess the potential to target the HNV-F protein glycans, we tested the binding of
2G12, a glycan reactive antibody previously noted for its broad specificity to diverse viral fusion
proteins and ability to neutralize influenza and HIV-1[34-36]. We did not detect any binding
between 2G12 and the HNV-F panel (**Supplemental Figure 9C**). We also tested the reactivity of
recombinant Griffithsin, a lectin discovered in *Griffithsia* red algae that has been investigated for
antiviral properties [37,38] and has been shown to be protective against NiV challenge in hamsters
[39]. Griffithsin bound to most of the NiV/HeV strains in the panel, while also binding to two pre-
fusion stabilized *Parahenipavirus* constructs, of SHN5-1 and GakV-1, specifically
(**Supplemental Figure 9C)**, underscoring the potential for a glycan-directed approach for broad
spectrum targeting of HNVs.

Using (SPR), we tested the binding of 22F5 to LayV-F ectodomains in various
conformational states, using two separate disulfide stabilized pre-fusion LayV-F constructs
described previously, that we refer to here as DS [30] and DSv2 [20]. Additionally, we tested binding
with and without competition with 4G5 (**Figure 2D**). 22F5 bound to LayV-F in both pre- and
post-fusion conformations, indicating conformational bispecificity, and its binding was mostly
unaffected by the presence of 4G5, indicating a distinct epitope. Given the strong and diverse

binding profile of 22F5, we selected it for further characterization, including sequencing and
structure determination **(Supplemental Figure 10-12)**.
299
300   Taken together, our findings align with the current understanding that Henipaviruses and
301 Parahenipaviruses have distinct antigenic profiles. Parahenipavirus F proteins are not bound by
302 known anti-NiV/HeV antibodies. However, the breadth of strains bound by our LayV-F-reactive
303 antibodies indicates that cross-neutralization of a sizeable portion of known Parahenipaviruses
304 with a small number of antibodies may be an achievable goal.
305
Structural Characterization of 22F5 Antibody
Using single particle cryo-EM, we determined a structure of the 22F5 Fab bound to the
post-fusion form of the LayV-C1-F protein, at a global resolution of 4.5 Å **(Figure 3A,**
Supplemental Figure 11, Table S2), with local resolution of ~3Å at the interface of 22F5 with
the F protein. 22F5 bound to the DII region [13] of LayV-F, with a few DI contacts as well. While
there have been several previously observed antibodies targeting DII epitopes in NiV-F and
HeV-F proteins [33], the only other available structure for an anti-LayV-F antibody, 4G5, details an
epitope that includes contributions from HRA and HRB [20]. Additionally, we determined the
structure of the 22F5 Fab bound to the LayV-F-DS ectodomain at ~4Å local resolution at the
interface (**Figure 3B Supplemental Figure 12, Table S2**), confirming that the 22F5 epitope is
accessible in both the pre- and post-fusion conformation of LayV-F. For both LayV-C1-F and
LayV-F-DS, 22F5 was seen bound at all three DII sites.
318
The 22F5 Fab interacts with both the pre- and post-fusion LayV-F ectodomains utilizing
both heavy and light chains. The L1, L3, and H2 complementarity-determining regions (CDR)
are particularly involved (**Figure 3C, Supplemental Figure 13**). In the pre-fusion conformation
of LayV-F, a stretch of residues within DIII known as the fusion peptide is inserted into an
interprotomer pocket formed by a neighboring protomer's DII [19]. During pre-to-post-fusion
conformational conversion, the fusion peptide leaves this pocket. The pre-fusion 22F5 epitope
includes surface-accessible portions of the fusion peptide, but in the post-fusion conformation,
these residues no longer contribute to the 22F5 epitope (**Figure 3C, bottom**). 22F5 binding
appears to rely heavily on polar interactions (**Figure 3D**). Specifically, heavy chain residues N54
and R57 contact LayV-F DII residues N384 and the main chain of Q398, respectively. In the
light chain, R27, Y32, and Y92 interact with DII residues D391, D393, and Q416, respectively.
Additionally, the 22F5 light chain N terminal residue D1 interacts with N285, a residue that
belongs to domain DI of the neighboring protomer. When bound to the pre-fusion conformation,
22F5 contacts the neighboring protomer DI via its CDRH2 and framework region residues. Due
to the shifting of protomers relative to each other during pre- to post-fusion conformational
conversion, 22F5 shifts its interaction with the neighboring protomer DI region, losing its
CDRH2 and heavy chain framework region contacts and gaining the light chain D1 contact with
the post-fusion F protein. (**Figure 3C and 3D**). Using SPR, we determined the affinity of 22F5

for both ectodomain constructs, as well as a heat-treated sample of the wild-type LayV-C1-F that
ensured uniform post-fusion conformation, with binding observed at low nM affinities in all
cases (**Figure 3E**). Interestingly, despite the loss of contacts with the fusion peptide residues
when bound to the post-fusion conformation of LayV-F, 22F5 bound tighter to the post-fusion
conformation than the pre-fusion conformation. Given that the fusion peptide is a flexible region,
it is possible that contact with it is entropically unfavorable, thereby explaining the improved
affinity with the post-fusion LayV-F where this contact was absent.
344
345   In summary, 22F5 binding and structural data describe an epitope that is accessible in
346 both pre-and post-fusion conformations and reveal a region on the *Parahenipavirus* F protein
347 that can be targeted for greater breadth than previously recognized. 22F5 is a valuable addition to
348 the antibody toolbox for the *Parahenipavirus* genus for which relatively few antibodies are
349 known.
350
Differential Scanning Fluorimetry of HNV F ectodomains
We assessed the stability of the purified F ectodomains using Differential Scanning
Fluorimetry (DSF), a label-free method that measures changes in intrinsic fluorescence as the
protein unfolds. The DSF profiles of the two wild-type proteins, NiV-M1-F and LayV-C1-F, and
one prefusion-stabilized NiV-F construct, NiVop08 [31], were consistent with our previous reports
[19]. With each peak in a DSF profile indicating a conformational transition, for the unstabilized F
ectodomains we observed one transition between 45-65ºC and one or more transitions at higher
temperatures, up to over 90ºC (**Figure 4A**). LayV-C1-F showed two transitions with a negative
peak at 50ºC and a positive peak at 86ºC. NiV-M1-F showed three transitions with a negative
peak 56ºC, and positive peaks at 76ºC, and 92ºC. NiVop08 showed two transitions, a negative
peak at 66ºC and a positive peak at 76ºC. We next measured the DSF profiles of the same set of
proteins after pre-incubation at 60ºC for 90 minutes, based on previous observations that heat
treatment could force pre- to post-fusion conformational conversion in *Paramyxoviridae* F
proteins [40]. Overlaying all DSF profiles revealed that the lower-temperature negative peak
present in all three proteins prior to heat treatment was eliminated in only the two wild-type
proteins after heat incubation (**Figure 4A**). NSEM analysis confirmed that the wild type proteins
have been converted to the postfusion conformation, as revealed by the characteristic elongated
six-helix bundle present in the 2D class averages (**Figure 4B**). The NiVop08 prefusion stabilized
construct retained the more compact shape characteristic of the prefusion state (**Figure 4B**). By
exposing NiV-M1-F and LayV-C1-F to a series of times and temperatures, we found that 50ºC,
15 minutes was the minimum amount of heat treatment sufficient to eliminate the pre-to-post-
fusion conversion DSF peak, indicating that the F protein population was predominantly in the
post-fusion state (**Supplemental Figure 14**). Together, these results indicate that the negative
DSF peak present around 45-60ºC is indicative of a pre- to post-fusion conformational change
taking place, and this DSF signature can be utilized to follow population level conformational
transition from the pre- to post-fusion forms.

377
Next, measuring DSF profiles for all purified F proteins for which there was sufficient
material purified, typically at least 5µg, we observed a wide range of conversion peak intensities
and temperatures (**Figure 4C-F**). While all proteins generated a large positive peak at high
temperature indicative of a denaturation event, not all proteins produced a detectable conversion
peak. 14 proteins had essentially no detectable signal prior to the high temperature peak (**Figure
4D**). For these F ectodomain samples, two-dimensional class averages from NSEM analysis
revealed the predominance of postfusion conformation for these proteins with no detectable pre-
fusion F species observed in the datasets, supporting the DSF results. Though not exclusively,
most of the proteins with no conversion peak are Parahenipaviruses, and inversely, all of the
Parahenipaviruses have no conversion peak, except for Langya virus strains. Many of the
Parahenipavirus F proteins could not be assessed due to insufficient purification yield, and these
results may suggest it could be due to inherent instability. Among the F proteins that generated a
conversion peak, there were shifts in temperature and intensity (**Figure 4E**). These changes did
not appear related to species differences, with NiV-M1-F and NiV-M3-F, separated only by one
amino acid mutation, being right- and left-shifted compared to the average, respectively. Both
Langya virus strains were the most left-shifted of the set, indicative of lower pre-prefusion F
stability. NSEM analysis showed a mix of pre- and postfusion conformations in this set,
therefore the presence of this negative DSF peak indicates some amount of prefusion
conformation present, rather than the presence of a uniform set of prefusion proteins. Between
the conversion peak and the final high temperature peak is typically a broad, positive peak,
present with differing intensities and shapes. Further investigation would be required to
determine if this peak is either part of a natural, yet undefined, conformational event or part of
the denaturation process.
401
Two proteins of the panel, AngV-F and the sequence-corrected version of GhV-F,
GhV(+A)-F (**Supplemental Note 1**), display DSF profiles that are outliers to the rest of the
panel (**Figure 4F**). Interestingly, both proteins displayed a profile that seemed closer to
NiVop08, with their high temperature positive peak significantly left-shifted. Two-dimensional
NSEM classes for these two proteins showed the presence of largely, but not exclusively, pre-
fusion conformations. Despite their apparent similarities to a pre-fusion stabilized F construct,
these are wild-type proteins that are expected to undergo normal conformational conversion,
barring unexpected and dramatic mechanistic differences. The ability of the AngV-F and
GhV(+A)-F proteins to undergo conformational conversion from the pre- to post-fusion states is
supported by presence of post-fusion F forms in the NSEM 2D classes (**Supplemental Figure
5**). We incubated these outlier F proteins under both the 60ºC, 90 minute and 50ºC, 15 minute
conditions. After incubation at 50ºC for 15 minutes, a condition under which NiV-F and LayV-F
proteins show effectively complete transition to the post-fusion conformation, we found that
AngV-F and GhV(+A)-F proteins retain much of their native DSF profile, suggesting greater

pre-fusion stability. Incubation at 60ºC for 90 minutes, however, was sufficient to induce a
dramatic change in their DSF profiles, suggesting more complete conformational conversion.
418
Since DSF is reliant on primarily Tryptophan residues to generate signal, it is possible
that differences in DSF profile could arise from differing number and position of Tryptophans;
however, the F ectodomain has only one Tryptophan that is almost universally conserved, with
only CedV-1-F mutated at this spot (**Supplemental Figure 15**). Furthermore, AngV-F contains
one additional Tryptophan that is unique to AngV-F. All F ectodomain constructs additionally
contain one Tryptophan in the foldon tag used to assist with trimerization and two in the twin-
strep tag used for purification. In general, sequence variability is likely not a significant factor in
the differences observed in the DSF profiles of HNV-F proteins. Our results support the
utilization of DSF as a rapid analytical technique requiring a small amount of protein for
assessing population-level pre-to-post fusion transition of HNV-F proteins. In this study, the
DSF analysis was central to our identification of two species that exhibit F pre-fusion
conformations that appear more stabilized than in other HNV species.
431
Cryo-EM Structures of AngV-F Protein
Based upon both amino acid sequence and pre-fusion stability as revealed by DSF
analysis, AngV-F has divergent properties from the currently characterized F proteins. Therefore,
we determined the structure of the AngV-F protein by cryo-EM single particle analysis (**Figure
5, Supplemental Figure 16-18, Supplemental Table 2**). The cryo-EM dataset revealed three
particle populations (**Figure 5A**). The most populated class was of the isolated F ectodomain
trimer, followed by a dimer-of-trimers population, and finally a population where the F proteins
formed a hexameric array. The AngV-F trimer was refined to a global resolution of 4.0 Å and
used for detailed examination of the F ectodomain structure and for comparing to the previously
known structures of other F proteins. In cryo-EM structures of the HNV-F proteins the stalk
region is typically poorly defined [15,19,33,41,42]. Our AngV-F cryo-EM structure revealed well-
defined density for the stalk, allowing atomic-level modeling.
444
The AngV-F ectodomain exhibited a larger central cavity compared to NiV-F and LayV-
F proteins. This expanded cavity is the result of both the stalk region not inserting as far into the
cavity as in other HNV-F proteins and the domains surrounding the cavity being spaced farther
apart (**Figure 5B**). In previously determined HNV-F structures, the helical stalk region begins
with a Lysine at its N-terminal end, thus positioning a trio of Lysines, one from each of the
protomers, at the bottom of the internal cavity. In AngV-F, we instead observed a Proline at the
beginning of the stalk (HRB) helix (**Figure 5C**). The surface electrostatics of this region are,
therefore, strikingly different at this position for AngV-F compared to NiV-F and LayV-F
structures. The proximity of the Lysines in LayV-F and NiV-F and their electrostatic repulsion
could be a source of metastability in the pre-fusion F protein, as charge repulsion may be a
mechanism to force apart the HRB helix during conformational conversion. The absence of this

Lysine trio and replacement with a Proline cap at the N terminus of the HRB helix may lend
greater stability to the pre-fusion form of the AngV-F protein. Notably, all species in our panel
have either a Lysine or Arginine at this site, with only AngV-F substituting with a Proline
(**Supplemental Data 1**).
460
Several glycans could be resolved (N61, N93, N353, N434 and N458), including ones
analogous to those previously defined in HNV-F structures [41,42]. The glycans shield known sites
of vulnerability in *Paramyxoviridae* F proteins, including at the apex (N61), near the fusion
peptide (N93 in Domain III), and on the stalk domain (N458). Interestingly, the glycan proximal
to the fusion peptide utilizes a non-canonical NNV sequence (**Figure 5D**). The MojV-F and
SHNV2-F proteins also have NNV sequences at this site that may be similarly glycosylated.
Glycans in the apex region near N61 and the HRB/stalk region near N458 are observed in many
HNV-F protein structures (**Supplemental Figure 19**). However, there is no AngV-F analog to
the N414 glycan of HeV-F and NiV-F. Instead, AngV-F contains two novel glycans in DI
(N434) and DII (N353). The non-canonical NNV glycan at N93 is also found at the same site in
HeV-F and NiV-F using canonical sequons, but interestingly, not in LayV-F. The differential
glycosylation patterns observed across diverse HNV-F species may play a role in determining
the potential for cross-reactivity, but critically, the presence of the NNV glycan in AngV-F
indicates that prediction of glycosylation through sequence alone may be difficult.
475
Interactions between the AngV-F trimers were mediated through intermolecular contacts
along the DI and DIII domains. These include hydrophobic interactions in DIII between L157
and V159 on neighboring ectodomains, both positioned on a loop that is part of an important
antigenic site [13,33] (**Figure 5E**). Furthermore, there are charge interactions involving H45 from
DI and T99 and F105 of DIII (**Figure 5E**). Similar oligomeric states between pre-fusion F
protein molecules (trimer, dimer-of-trimers, trimer-of-trimers) were also found in the cryo-EM
dataset of a Hendra virus F protein (HeV-α1.2-F) (**Supplemental Figure 18**). AngV-F dimers
resemble "mirror-like" protein dimers, with each exterior interaction surface of a protomer
available for dimerization. These dimers, in turn, interact with protomers from three other
trimers, forming hexameric structures. Each trimer is consistently aligned within the plane of the
hexameric assembly, leading to a horizontally level lattice, distinct from an NiV-F crystal
structure in which the lattice was not within one plane [41].
488
Taken together, our cryo-EM structures revealed that, while maintaining the overall
conserved HNV-F architecture as observed in previously characterized HNV-F proteins, key
mutations imparted notably distinct pre-fusion characteristics on the AngV-F protein. They also
revealed multimerized pre-fusion F proteins, adding to the growing body of literature that
suggests a role for the multimeric assemblies in the context of the virion and suggests a distinct
mode of F protein multimerization leading to the formation of hexameric lattices for the AngV-F
protein.

Structure-guided Pre-fusion Stablization of diverse HNV-F Proteins

We hypothesized that the proline substitution observed at the start of the HRB helix, unique to AngV-F, was the cause of the increased pre-fusion stability. We expressed a series of HNV-F constructs from a variety of HNV species incorporating this proline substitution. Available HNV-F structures indicate that the site analogous to K453 in NiV-M1-F is consistently positioned at the N-terminal start of HRB, and even among other species for which structures are not available, the region surrounding this site is relatively well-conserved **(Figure 6A, Supplemental Data 1)**.

All of the proline mutants were able to be purified in sufficient amounts to permit downstream quantitation, with yields per transfection volume mostly exceeding those of the wild-type construct **(Figure 6B-D, Supplemental Figure 20A)**. In the case of the SHNV5-1-K455P mutant, the yield sharply decreased, but yet all mutants, including SHNV5-1-K445P-F, DSF analysis revealed significant pre-fusion stabilization **(Figure 6B-D, Supplemental Figure 20B)**. The trademark fusion conversion peak was present in all constructs, often with greater intensity than the wild-type, or demonstrating a right-shift of conversion temperature, possibly indicating higher stability of the pre-fusion conformation. In the case of the NiV, HeV, and LayV mutants, the 70-80ºC peak was also present with higher intensity than the wild-type. Whereas GakV-1-F had displayed exclusively post-fusion conformation through both DSF and NSEM analysis **(Figure 6D),** the GakV-1-K452P-F DSF profile was dramatically altered, even appearing similar to the profile of the pre-fusion NiVop08 mutant or outliers like AngV-F and GhV(+A)-F. NSEM analysis confirmed the findings from DSF, with pre-fusion 2D classes observable with all mutants. The altered 2D classes of GakV-1-K452P-F, as with it's DSF profile, was particularly striking. Whereas the wild-type classes contained solely post-fusion conformations, the mutant classes were almost universally pre-fusion. Despite the strong pre-fusion stabilization across all species, it was still common to observe post-fusion classes, reflecting that as with AngV-F, this mutation stabilizes pre-fusion conformation without preventing conversion **(Figure 6B-D, Supplemental Figure 20C)**.

We assessed the binding of the NiV and HeV-based mutants, NiV-M1-K458P-F and HeV- α1.2-K453P-F, to the pre-fusion specific 4B8 antibody. Strong binding was observed between 4B8 IgG and all F constructs tested: both wild-type and mutant NiV-M1-F and HeV-α1.2-F, and NiVop08 **(Supplemental Figure 20D)**. However, after incubation at 50ºC for 15 minutes, while binding to NiVop08 was maintained, binding to wild-type NiV/HeV was nearly eliminated. The HeV proline mutatnt's binding to 4B8 was similarly eliminated, while the NiV mutant's binding was only moderately reduced. Taken together, our results indicate that pre-fusion stabilization of NiV/HeV through the substitution for the HRB start proline lends greater pre-fusion state stability but still allows for conformational conversion and antigenicity consistent with wild-type constructs.

537   We collected larger NSEM datasets and reconstructed 3D classes to quantify pre- and
post-fusion ratios for these mutants and their wild-type counterparts. In all cases, the proportion
of pre-fusion particles was increased in the mutant construct ccompared to wild-type
(Supplemental Figure 21A-F). Interestingly, even for GakV-1-F and SHNV5-1-F, species
where no pre-fusion conversion peak was present in DSF, a small amount of pre-fusion classes
were detected in the larger NSEM datasets **(Supplemental Figure 21A-B, F)**. Most striking was
the conversion of GakV-1-F from ~10% pre-fusion classes, the least of any species, to over 75%
pre-fusion with the proline mutant, the most of any species **(Supplemental Figure 21A-B)**.
Although the use of NSEM results in low-resolution 3D volumes, it is still apparent that the
typical pre- and post-fusion class shapes are observed in all species, indicating that the proline
mutation has not significantly altered the pre-fusion conformation.

549   In summary, the introduction of this proline presents an effective and translateable means
550 of pre-fusion stabilization for HNV-F proteins, and one that is expected to have minimal impact
551 on any of the antigenic sites on the surface of the protein.

553 ***Purification and Characterization of Diverse HNV-G Head Domains***
554   To analyze our panel of HNV-G proteins, in this study we focused on the isolated head
domain, which is responsible for receptor binding and is an important antigenic site [13]. To allow
for the previously described head domain sequences to be secreted in a mammalian expression
system, we added an artificial secretion signal [43], and appended a C-terminal 8x His tag. The G
head domain constructs were transiently transfected and affinity purified with cobalt resin
affinity chromatography, followed by SEC. The typical SEC profile for the head domain proteins
reflects the simple nature of their single-domain fold. All proteins eluted with a consistent single
main peak (**Supplemental Figure 22**), typically with a small, higher molecular shoulder or peak
likely consisting of aggregates. Yields for the head domains ranged from 2.5 to 35.3 mg/L
(**Supplemental Figure 1**), with the majority yielding above 10 mg/L.

565   It has previously been noted that Langya and Mojiang virus attachment proteins do not
bind to Ephrin B2 or B3 ligands (EFNB2/B3), the receptors used by Henipaviruses [20,44]. Through
BLI and SPR experiments, we assayed the binding of all G head domains in our panel to
recombinant Fc-tagged Ephrin-B2 and -B3. As expected, all Nipah and Hendra virus head
domains bound to both B2 and B3, with stronger binding observed for B2 rather than B3 (**Figure
7A, Supplemental Figure 23A-B**). CedV-1-G and GhV-G also bound to B2, with very faint
binding to B3. Consistent with the previous observations, Langya and Mojiang virus G head
domains, as well as the rest of the panel, including all Parahenipaviruses, did not show any
appreciable binding to either B2 or B3.

We assessed the antigenicity of our G head domain panel with a series of previously
characterized anti-NiV/HeV-G antibodies: HENV-26 and -32 [16], m102.3 and .4 [25], nAH1.3 [45],
and 1E5 [26]. We also included the same Griffithsin construct used with the F panel. The known
anti-NiV/HeV antibodies demonstrated broad, strong binding to all tested NiV and HeV strains
(Figure 7B, Supplemental Figure 23C-D). There were lower levels of binding observed for
some of these antibodies outside of NiV/HeV strains, particularly with Ghana virus. Griffithsin
showed moderate binding to several strains, albeit inconsistent and not seemingly linked to
sequence similarity. It bound most tightly to the SHNV3-G and SHNV11-G head domains.
Although it did not show consistent binding to NiV/HeV proteins, as with HNV-F, nevertheless,
the ability to bind to several *Parahenipavirus* G proteins is notable, given the lack of known
binders for these novel strains. Slight variations in binding were observed through ELISA,
mostly in the form of low to moderate levels of 1E5 binding to GhV-G, DarV-K-G, and MelV-G
(Supplemental Figure 23D).
588
We used DSF to assess the thermostability of the G head domains. Unlike F proteins, the
head domains are not known to undergo a dramatic conformational change when heated, and
most proteins in the panel generated a profile with a single peak between 60-70ºC, with some
small shifts in inflection temperature that were largely consistent within species groupings.
(Supplemental Figure 24A-B). Several species generated profiles distinct from the most
common result, such as broad, negative, or double peaks **(Supplemental Figure 24C-D)**. Unlike
the relatively high conservation of Tryptophan positions in F proteins, G proteins display a much
higher level of sequence diversity (**Supplemental Figure 15**). Indeed, there are substantial
differences in Tryptophan positions in species that generated outlier profiles, CedV, GhV, AngV,
and SHNV2 especially. The variability of Tryptophans in the G protein across species groupings
precludes genus-wide comparisons of DSF profiles, yet these results provide interesting
comparative insights within species groupings that may have implications for differences in
receptor binding and virus fitness between species. As observed in the case of the SARS-CoV-2
spike protein, where thermostability of the receptor binding domain (RBD) is a property that is
optimized during virus evolution [46-48], stability of the G head domain may impact its ability to
bind receptor and antibodies, thus impacting its biological function.
605
Structure of Gamak Virus Attachment Protein Head Domain
HNV-G proteins are tetramers (dimer of dimers), with each monomer composed of a
helical stalk domain, a neck domain and a 6-bladed, β-propeller head domain where the receptor-
binding site is located [13]. When comparing the sequence diversity of the HNV-G proteins, we
noted that the C-terminal end of G head domains are a site of substantial variability **(Figure 7C,**
Supplemental Data 2). GakV-G has among the longest C-terminal end, over 30 residues longer
than NiV-G. A crystal structure of the GakV-2-G protein head domain at 1.4 Å resolution
(Figure 7D, Supplemental Table 3) showed the expected 6-bladed β-propeller architecture that
is well-conserved among HNV-G proteins. A well-resolved glycan was observed in the region

that is analogous to the Ephrin (EFN) receptor binding surface in the NiV-G head domain
(**Figure 7E).** The presence of this glycan further illustrates the changed receptor specificity of
the Parahenipaviruses, as it would likely cause a steric hindrance to Ephrin binding if present in
NiV or HeV. The elongated C-terminal end was resolved in our structure, revealing a novel
domain spanning residues 606 to 628 that formed a three-stranded β-sheet stacked against blade
5 of the β-propeller (**Figure 7D, F, Supplemental Figure 25**). This additional compact and
ordered domain is distinct from the previously known structures of *Henipavirus* G protein head
domains. Furthermore, the N-terminus of the head domain appeared well ordered and packed
against the 6-blade β-propeller core (**Figure 7G**). Residues 194-199 threaded between blades 5
and 6, contributing a β-strand to blade 6 as it continued to lead into blade 1. This stretch of
residues also contacted blades 2, 4, and 5, thus forming a connection between different
secondary structures within the β-propeller. Taken together, the structure of the GakV G head
domain illustrates the structural diversity that can be accommodated within the conserved β-
propeller fold to possibly impact receptor tropism and antigenicity.
629
630   **Discussion**
631   Over the past few years, there has been a rapid expansion of identified species and strains
in the *Henipavirus* genus, ultimately leading to the separation of these species into the
Henipavirus and *Parahenipavirus* genera [10]. Given the history of zoonotic transmission with
these viruses, characterization of these novel species is an important step for pandemic readiness.
Here we characterize a diversified panel of HNV F and G proteins to construct a panel that
reflects the global diversity of HNVs. Until now, many of the strains in our expanded panel of
Henipaviruses were known by their sequences alone, their surface glycoproteins totally
uncharacterized and their relationships to other Henipaviruses unknown. Focusing particularly
on Parahenipavirsues, closely related to Henipaviruses such as NiV and HeV, we elucidate their
genetic diversity, antigenic relationships, structural novelties and mechanistic features.
641
642   Purifying and characterizing the F protein ectodomains of these strains has revealed that
despite low sequence identity, HNV-F proteins share many architectural and biophysical
similarities, a trend we previously noted by comparing Langya virus to Nipah virus [19]. One of the
most notable similarities was the presence of some level of oligomerization between F trimers.
This was apparent from the SEC profiles, but the presence of trimer multimers did not seem to
correlate with other parameters, such as purification yield, metastability, or phylogeny. It appears
instead that the formation of these complexes is transient and dependent on the concentration and
environment of the F protein, as suggested by the absence or very small proportions of oligomers
detected by mass photometry or NSEM where sample concentration is much lower than during
size-exclusion chromatography and cryo-EM. The ubiquity of this type of interaction indicates
that oligomerization of F proteins is likely a conserved trait within HNVs.
653

F protein oligomerization was most striking in the case of Angavokely virus, where the
formation of a hexameric lattice of F protein trimers was observed in the cryo-EM datasets. The
existence of a hexamer-of-trimers arrangement has been noted previously with NiV [41], though
the biological relevance was limited by the use of crosslinking to stabilize the arrangement. Our
structure demonstrates the ability of AngV-F to multimerize in this way without any such
assistance and, critically, without the involvement of the transmembrane domain, viral envelope,
cytoplasmic domain, or viral matrix protein. The hexameric lattice is formed purely through
ectodomain interactions, validating the characterizations of inter-trimer interactions previously
reported for NiV [30], yet distinct in the implicated residues, with the AngV-F interaction involving
DI and DIII, while the NiV-F interaction is dominated by DII residues. Previous studies have
defined the lattice of *Paramyxoviridae* and *Pneumoviridae* F proteins, with various arrangements
being determined. In one case, hexameric lattices have been observed, as with a whole-virion
tomography structure of parainfluenza virus 3 [40]. In others, such as with measles virus and
respiratory syncytial virus, alternate arrangements of fusion and attachment proteins have been
observed [29,49]. Our results with AngV-F suggest that HNV-F proteins may adopt a hexameric
arrangement, though structural studies of pseudoviruses and whole virions would help elucidate
the physiological relevance of this finding. Furthermore, it cannot be ruled out that the formation
of a hexameric F lattice may comprise one stage of HNV-F functionality, as the arrangement
could shift during some type of maturation event or during G-mediated triggering.

Our biophysical characterizations of HNV-F proteins give us a rapid and inexpensive tool
with which to assess metastability without relying on time-consuming structure determination.
Using this assay we were able to identify distinct signatures for pre-to-post fusion conversion
and F protein denaturation, revealing how differences in sequence or structure could impact
metastability. Though there are limitations in biological relevance working with soluble F_0
ectodomains, this assay has proven reliable in quickly detecting altered pre-fusion stability in
HNV-F proteins. It was through this DSF assay that we identified the strongly pre-fusion
stabilized character of AngV-F, leading to our discovery of the HRB helix proline substitution as
a translatable means for pre-fusion stabilization. Previous attempts to translate successful pre-
fusion stabilization strategies for NiV-F to Parahenipaviruses have required structure-based
evaluation of analogous sites to the disulfide, cavity-filling, or proline substitution strategies used
previously [20,30]. However, the region surrounding the start of the HRB helix as well as
specifically the positively charged residue substituted for a proline are so well-conserved as to
have allowed successful and efficacious transfer of the stabilizing mutant to each species
attempted without further decision on positioning of the substitution. Additionally, while
strategies like the triple mutation found in NiVop08 appear to fully lock the F protein in a pre-
fusion conformation, the HRB start proline more moderately stabilizes without completely
preventing conformational conversion. Though the incorporation of such a mutation would
impart significant limitations on the biological relevance of any studies that evaluate
conformational change in a mutated F construct, its utility is highlighted in situations where

wild-type constructs do not produce any pre-fusion protein whatsoever, as we have seen with
SHNV5-1-F and GakV-1-F.

697   DSF analysis of G head domains also reveals a diversity of thermostability patterns.
Although G head domains are comprised of a single domain 6-stranded β-propeller fold and are
not known to have any major internal conformational rearrangements as part of their receptor-
binding mechanism, some studies have indicated that receptor binding by HNV-G proteins could
effect subtle changes in protein flexibility that do not manifest as large-scale conformational
events [50]. The differences in thermostability could potentially correlate with mechanistic
differences between strains; however, more structural data detailing the structural changes that
take place after receptor binding in G proteins will be needed to confirm this. From our crystal
structure of the Gamak virus head domain, we can observe other likely sources of mechanistic
differences between species. Though receptors for the Parhanehipaviruses remain unkown, the
presence of the glycan in the traditional Ephrin-binding suggests an altered mode of receptor
engagement. While the glycan may not be solely responsible for the lack of Ephrin binding in
GakV-G, it would likely hinder binding of a similar protein receptor in the EFNB2/3 site,
suggesting that GakV either uses a smaller receptor or perhaps a different receptor binding site
entirely. This would not be without precedent in Paramyxoviruses. For example, though
EFNB2/3 engages the same face of the head domain in NiV and HeV that sialic acid does in
other Paramyxoviruses [51,52], the measles virus receptor, CD150, binds at the side surface of the
head domain, making major contacts along blades 5 and 6 [53].

716   The C-terminal diversity in the head domains, and especially the additional exterior blade
717   revealed in the GakV-2-G structure, may be the source of mechanistic changes as well. Together
718   with the altered arrangement of the N- and C-terminal ends of the head domain we observed,
719   these features could suggest a different pattern for quaternary interactions in GakV-G
720   ectodomain tetramers, different types of conformational changes within GakV-G after receptor
721   binding, or may even serve as a possible binding site for the as of yet undiscovered receptor.

723   While several anti-NiV and anti-HeV neutralizing antibodies have been well-
characterized, the antigenicity of novel HNV strains had not yet been explored. By assessing the
binding of a panel of both previously identified anti-HNV antibodies and newly discovered
antibodies elicited through vaccination, we can now better describe the antigenic landscape of
HNV proteins. As expected, we saw little ability of anti-NiV/HeV antibodies to bind to non-
NiV/HeV proteins. Most interestingly, we found clear antigenic overlap between the F proteins
of LayV, MojV, SHNV5, and to a lesser extent, GakV. Both a previously reported anti-MojV-F
antibody, 4G5, and our vaccine-elicited antibodies, 22F5 especially, bound to these strains.
When considering our phylogenetic analysis, both by full genome and amino acid sequence, it
can be seen this cross-reactivity spans distantly related strains. SHNV5 appears to be more

distantly related to LayV than HeV is to NiV. GakV is even more distant phylogenetically,
appearing to be roughly as distant from LayV as CedV is from NiV.
735
While the G and F proteins are not particularly heavily glycosylated relative to other viral
glycoproteins, they ultimately do exhibit a varied glycosylation landscape, with glycans
appearing in important antigenic sites in some species. While the lectin griffithsin only showed
moderate levels of binding to most antigens tested here, it was able to bind to a very diverse set
of HNV-G head domains. Most interestingly, its strongest binding was to the SHNV3 and
SHNV11-G head domains, proteins for which there are currently no known antibodies or ligands
that can bind them. As investigation of griffithsin for antiviral potency across several families
continues, it may prove a useful tool for analysis of novel HNV proteins.
744
With a group of viruses exhibiting such great sequence diversity, one major concern in
the event of a possible widespread outbreak of disease in humans is that emergent infective
strains may escape immunity conferred from prior infection or immunization with other HNV
strains. This phenomenon can be observed with yearly outbreaks of new influenza strains or with
the progression of SARS-CoV-2 evolution, where new strains emerged and quickly dominated
the pool of circulating virus as they evaded prior immunity [54,55]. A key focus of efforts to address
this possibility has been the design of immunogens that can elicit antibodies with broad coverage
of the currently exisitng and future diversity of strains. Being able to draw antigenic boundaries
within the *Henipavirus* and *Parahenipavirus* genera is a foundation for similar efforts, and here
we see that while the prospect of cross-reactivity over the entire genus remains elusive, there is
already demonstrated cross-reactivity among a large portion of the Parahenipaviruses. While it
will be important to assess this observed cross-reactivity in neutralization assays and animal
challenge models, there is currently limited knowledge of both the host receptors for
Parahenipaviruses and of the proper cell lines or animal models to study infection. While some
progress has been made in identifying permissive cell lines for Parahenipaviruses[44,56], the rate of
fusion is typically much lower than seen with more well-studied Nipah/Hendra models,
indicating that such viral entry assays could be in need of further optimization. Ultimately, in the
absence of robust experimental systems to study the virological properties and the breadth of
protection from potential HNV infections, the discoveries reported here build a critical
foundation for future exploration of *Parahenipavirus* antigenicity.
765
766   Ultimately, this broad characterization of HNV proteins provides a set of essential
767 biophysical and biochemical data for many species and strains that, to this point, had only been
768 known as a sequence in a database. As these novel species are studied in more depth, our
769 analysis can be used to provide context for the comparison of other key aspects of *Henipavirus*
770 biochemistry, structure, and immunology.
771
Acknowledgements

Cryo-EM data were collected at the Duke Krios at the Duke University Shared Materials
Instrumentation Facility (SMIF), a member of the North Carolina Research Triangle
Nanotechnology Network (RTNN), which is supported by the National Science Foundation
(award number ECCS-2025064) as part of the National Nanotechnology Coordinated
Infrastructure (NNCI). We thank Dr. Nilakshee Bhattacharya for assistance with microscope
alignments. This study utilized the computational resources offered by Duke Research
Computing (http://rc.duke.edu; NIH 1S10OD018164-01) at Duke University. This research used
resources of the National Synchrotron Light Source II, a U.S. Department of Energy (DOE)
Office of Science User Facility operated for the DOE Office of Science by Brookhaven National
Laboratory under Contract No. DE-SC0012704. Use of the NYX beamline 19-ID at the National
Synchrotron Light Source II was supported by the New York Structural Biology Center.
NYX detector instrumentation was supported by grant S10OD030394 through the Office
of the Director, National Institutes of Health. This work was supported by funding from the
Translating Duke Health Initiative, Duke School of Medicine, and NIH R01 AI 165147 (P.A.).
We thank Fred Alt, Ming Tian and Sai Luo for providing the $V_H1-2R^{JH2}/V\kappa1-33R^{CS\Delta/hTdT}$ (SE13)
mice, Hannah Violette and Nicholas Levering for technical assistance, and Nilakshee
Bhattacharya for assistance with cryo-EM data collection.
790

Author contributions: Conceptualization – A.J.M. and P.A.; Methodology –A.J.M., A.B.,
B.F.H. and P.A.; Investigation – A.J.M., M.L., J.J.L., A.B., M.D., M.B., R.P., X.L., M.B., A.N.,
X.H., A.M., U.K., K.S., V.I., S.S., C.S.P., R.D.A., P.D., K.J., Y.L., R.J.E., B.F.H., P.A. Data
Curation – A.J.M., M.L., J.J.L, A.B. and P.A. Validation – A.M., M.L., J.J.L, A.B. and P.A..;
Visualization – A.J.M., M.L., J.J.L, A.B. and P.A.; Writing - Original Draft – A.J.M., A.B. and
P.A.; Writing - Review & Editing – all authors; Supervision – A.J.M., K.W., R.J.E, K.O.S.,
B.F.H. and P.A.; Project Administration –A.J.M. and P.A.; Funding acquisition – B.F.H. and
P.A.
799

800   **Declaration of interest.**
801   A.J.M., M.L., J.J.L, A.B., B.F.H. and P.A. are named in provisional patents submitted on the
802   methods for stabilizing the pre-fusion HNV F and G proteins based on the findings reported in
803   this paper. Other authors declare no competing interests.
804

805   **Data and Material Availability**
806

Cryo-EM reconstructions and atomic models generated during this study are available at
wwPDB and EMBD (www.rcsb.org; http://emsearch.rutgers.edu) under the following accession
codes: AngV-F trimer - EMD ID: EMD-48423 and PDB ID: 9MNH; AngV-F dimer-of-trimer -
EMD ID: EMD-48535 and PDB ID: 9MQN. The crystal structure of the GakV G protein head
domain was deposited with the PDB ID: 9EHU.
All materials will be made available upon request.

Ethics Statement

All mice were cared for in a facility accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care International (AAALAC). All study protocols and all
veterinarian procedures were approved by the Duke University Institutional Animal Care and
Use Committee (IACUC).

Environment: All rooms are on a 12/12 light cycle unless otherwise requested. Heat and
humidity are maintained within the parameters outlined in The Guide for the Care and Use of
Laboratory Animals and animals are fed a standard rodent diet. Breeding or specialty diets will
be provided upon request. Rodents and Guinea pigs are housed in individually ventilated micro-
isolator caging on corn cob bedding. DLAR will provide alternative bedding based on scientific
need. Mice are changed every two weeks, rats are changed twice a week, and Guinea pigs are
changed three times a week or more frequently as needed. Group housing of up to 5 mice per
cage is strongly encouraged. Environmental enrichment for singly housed animals will be
provided unless an exception is granted by the IACUC.

Methods

Phylogenetic Analysis

Candidate sequences were identified by using the NCBI Protein BLAST tool [66]. Nipah-Malaysia
sequence NC_002728 was used as an input sequence. Sequences were aligned using the MAFFT
algorithm [67]. We removed any sequences for which there were gaps in the amino acid sequence,
ensuring each entry contained a full ectodomain protein sequence. The final tree was built as a
UPGMA based on the distance matrix using the Tree Viewer software [68].

Protein Production

For HNV proteins, human codon-optimized DNA sequences were synthesized by GeneImmune
Biotechnology and cloned into a pαH plasmid vector. Fusion protein ectodomain sequences
(**Supplemental Data 1**) were followed at the C-terminal end by a foldon trimerization domain,
HRV3C protease site, 8x his tag, and a twin-strep tag (IBA Lifesciences) Attachment protein
head domains (**Supplemental Data 2**) had an artificial secretion signal, secrecon [43], added to the
N-terminal end and an 8x his tag added to the C-terminal end. HNV protein plasmids were
transiently transfected into HEK 293 cell lines, either Expi293 or 293F (Thermo Fischer
Scientific) (**Supplemental Table 1**). The cells were allowed to incubate at 37ºC, 8% CO_2 and the
supernatant was harvested 5 days post-transfection.

Fusion proteins were purified by first sequestering free biotin by applying BioLock blocking
solution (IBA) and then using the Strep-Tactin affinity chromatography resin (IBA). Eluted
protein was then further purified using a Superose 6 Increase 10/300 GL size-exclusion column

854   (Cytiva) with PBS buffer at pH 8. The elution from SEC was spin concentrated with 100kDa
855   filters and flash frozen with liquid nitrogen.
856
Attachment protein head domains were purified first by sequestering EDTA by adding 2mg of
Cobalt Chloride per 1L of supernatant. TALON Cobalt Resin (Takara) was used for purification,
with 20mM HEPES and 150mM NaCl at pH 8 as a buffer, adding 50mM Imidazole for elution.
Proteins were further purified with a Superdex 75 Increase 10/300 GL SEC column (Cytiva),
again using the HEPES-NaCl buffer. The elution from SEC was spin concentrated with 10kDa
filters and flash frozen with liquid nitrogen.
863
Antibody human codon-optimized DNA sequences were synthesized by GeneImmune
Biotechnology and cloned into pVRC8400 plasmid vectors. Heavy chains were designed to
begin with the beginning of the antibody sequence and continue through the human IgG1 Fc
region. Light chains included both the VL and CL domains. Depending on the sequence source,
some antibody sequences either utilized mouse or human VL and VH domains. Mouse anti-NiV-
F fabs were designed to end after the mouse CH1 domain and had an 8x his tag added to the C-
terminal end, as described previously [33].

Plasmids encoding the heavy and light chains of the antibodies IgG 1E5, nAH1.3, 4G5, and
DH851.3, or an Fc-tagged Griffithsin construct, were co-transfected into Expi293 cells at a 1:1
ratio, using the ExpiFectamine 293 Transfection Kit (Thermo Fisher Scientific, Cat. No.
A14525), according to the manufacturer's instructions. Following a six-day incubation period
post-transfection, the cells were harvested, and the culture supernatant was clarified by filtration
through a 0.2 μm PES membrane filter to remove cellular debris. IgG purification was
subsequently carried out using Protein A affinity chromatography. The filtered supernatant was
passed through the Protein A affinity column (Pierce[TM] Recombinant Protein A Agarose Cat No.
20334), and the bound IgG was eluted using IgG elution buffer by adjusting pH via Tris Base.
Eluted fractions were pooled and concentrated with Centricon-70 30 kDA filter (Millipore
Sigma) followed by size-exclusion chromatography using a HiLoad 16/600 Superdex 200pg
column (Cytiva), pre-equilibrated with 1× phosphate-buffered saline (PBS, pH 7.4) containing
0.02% sodium azide to prevent microbial contamination. The purified IgG was collected,
concentrated, and analyzed for purity and integrity by SDS-PAGE.

Anti-NiV-F Fabs were purified using the same Cobalt resin-based procedure as described above
for head domains.
887
To generate Fab fragments for 22F5 mouse IgG and 1C8 mouse IgG, 2 mg of each IgGs were
passed through Zeba Spin Desalting Columns (ThermoFisher), then washed with digestion buffer
containing 35 mg cysteine. IgGs were incubated with 0.250 ml of the 50% slurry of
Immobilized Papain resin (ThermoFisher) followed by incubation with digestion buffer
containing 35 mg cysteine at 37°C overnight in microcentrifuge tubes. The digested Fabs were

separated from the Immobilized Papain by centrifuging at 5000 x g for 1 minute, followed by
washing with digestion buffer. After digestion, the mixture was subjected to protein A affinity
chromatography (ThermoFisher), then monitored by SDS-PAGE to confirm Fab generation. To
further purify the Fab fragments, Size-Exclusion Chromatography (SEC) was used for
purification of the Fab fragments using Superose 6 Increase 10/300 column GL (Cytiva). The
sample was loaded onto the column at a volume of 0.5 mL and the elution was carried out with
PBS at a flow rate of 0.5 mL/min. Fractions were collected, yielding a final concentration of 3.2
mg/mL and 4.2 mg/ml for 22F5 Fab and 1C8 Fab, respectively. The purified Fab was stored at
−80°C.
902
903 The ELISA control antibody Ab82 was purified as described previously [69].
904
DSF
Samples were analyzed using a Prometheus Panta (Nanotemper Technologies). All samples were
diluted to 0.125mg/mL using PBS, pH 8. Roughly 10µL was added to glass capillaries in
triplicate for measurements. The instrument was programmed to measure 350nm and 330nm
fluorescence from 35.0-95.0ºC using a 6.0ºC/min temperature gradient. All curves reported
represent averages from the triplicate readings.
911
BLI
Bio-layer interferometry (BLI) was employed to assess the binding between HNV proteins and
various antibodies. For fusion proteins (Figure 2), the analysis was performed using an Octet
RH16 (Octet RED384) system (Sartorius) at 25°C with kinetics buffer (Sartorius) as the running
buffer. HNV-F proteins with the twin-strep tag at 6 µg/mL were captured onto Streptavidin (SA)
Biosensors (Sartorius) for 300s, followed by a 60s wash in kinetics buffer. The biosensors were
then exposed to 20 µg/mL mAbs or 50 µg/mL Fabs for 300s to allow for association with the
fusion protein. Dissociation in kinetics buffer was monitored for an additional 300s. Sensor data
was analyzed using Octet Analysis Studio (Sartorius), with reference biosensor and zero-analyte
control sensorgrams subtracted from the raw data to obtain the curves corresponding to specific
binding events. For additional fusion protein experiments (Supplemental Figure 9), the analysis
was performed with the same equipment, tips, and buffer. HNV-F proteins were loaded at
6µg/mL for 300s and equilibrated in buffer for 60s before a 120s association step and 200s
dissociation step. All analytes were at 50µg/mL. Regeneration with 10mM Glycine, pH 1.7 was
employed, using tips for 6 cycles and regenerating with 10s pulses between regeneration solution
and buffer. SARS-S2-HexaPro [70] was loaded onto a tip as a reference sensor. Kinetics buffer was
used as a reference sample. Double reference subtraction was performed, except for in the case
of Griffithsin IgG, which bound to the SARS-S2-HexaPro, so only reference sample subtraction
was used. For each cycle, NiVop08 was loaded and bound to 4B8 Fab, and the signal relative to
the first use of the tip was used to adjust the response values of all association curves during that
cycle. For attachment head domains with human Fc-containing Abs, the analysis was performed

using an Octet RH16 (Octet RED384) system (Sartorius) at 30ºC with HBS-EP+ Buffer (Cytiva)
as the running buffer. Antibodies at 2 µg/mL were loaded onto anti-human antibody capture
(AHC) biosensors (Sartorius) for 300s, followed by a 60s buffer baseline. Association with head
domains at 25 µg/mL lasted 120s, followed by dissociation in buffer for 200s. Between cycles,
biosensors were regenerated by alternating 3x in 10mM Glycine pH 1.0 buffer and running
buffer for 5s each. Sensors were used for no more than 10 cycles of regeneration. Double
reference subtraction was performed using both a control-loaded sensor and a zero-analyte
reference sample.
941
SPR
For 22F5-LayV-F interactions, binding and kinetic assays were performed on a T-200 Biacore
system (Cytiva) at 25°C. All the binding and kinetic experiments were carried out in the HBS-
EP+ (10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA and 0.05% surfactant P-20) running
buffer. For the binding assay, an anti-Fc mouse SPR chip was used to capture 200nM of 22F5
IgG at 10µl/min flow rate and 50nM of LayV-F ectodomains as analyte were run at 30µl/min
flow rate and association and dissociation were monitored at 120 seconds. In the competitive
assay, 200nM of 4G5 IgG was captured on an anti-Fc human SPR chip at 10µl/min and analyte
as 22F5 Fab with LayV-F ectodomain complex in 5:1 ratio was flowed at 30µl/min flow rate for
60 seconds. SPR SA chip was used to capture the 50nM of the LayV-F ectodomains at 5µl/min
flow rate by biotin tag for kinetics analysis. 22F5 Fab 50nM with two-fold dilution (50nM,
25nM, 12.5nM, 6.25nM and 3.12nM) as analyte was flowed with 50µl/min flow rate and
association and dissociation times were analyzed at 60 and 240 seconds, respectively. For the
reference curves, we kept the same parameter in reference flow cells without protein capture.
The sensorgrams were blank corrected and analyzed in the Biacore T-200 evaluation software.
957
For Ephrin-HNV-G interactions, Binding experiments were performed on a Biacore T-200
(Cytiva) with HBS buffer supplemented with 3 mM EDTA and 0.05% surfactant P-20 (HBS-
EP+, Cytiva, MA). All binding assays were performed at 25°C. Ephrin binding to head domains
was assessed using a Series S CM5 chip (Cytiva, MA), which was labeled with anti-human IgG
(Fc) antibody using a Human Antibody Capture Kit (Cytiva, MA). Ephrin was coated onto the
chip at 12.5 nM (120 s at 5 µL/min). Head domains were injected at 100 nM over the ephrin
using a single injection (60 s on time, 180 s off time at 50 µL/min). The surface was regenerated
with 3 pulses of a 3 M MgCl$_2$ solution for 10 s at 100 µL/min.
966
967
Negative-Stain Electron Microscopy
Frozen samples from -80 °C were thawed at room temperature for 5 minutes. Samples were then
diluted to 40 µg/mL with 0.02 g/dL Ruthenium Red in HBS (20 mM HEPES, 150 mM NaCl pH
7.4) buffer containing 8 mM glutaraldehyde. After 5-minute incubation, glutaraldehyde was
quenched by adding sufficient 1M Tris stock, pH 7.4, to give 80 mM final Tris concentration and

incubated for 5 minutes. Quenched sample was applied to a glow-discharged carbon-coated EM

grid for 10-12 seconds, blotted, consecutively rinsed with 2 drops of 1/20X HBS, and stained

with 2 g/dL uranyl formate for 1 minute, blotted and air-dried. Grids were examined on a Philips

EM420 electron microscope operating at 120 kV and a nominal magnification of 49,000x, and

images were collected on a 76 Mpix CCD camera at 2.4 Å/pixel. Images were analyzed by 2D

class averages using standard protocols with Relion 3.0 [71].

Mass Photometry

A TwoMP (Refeyn) mass photometer was used for analysis. The AcquireMP software was used

for calibration and data acquisition. Calibration was performed with a three-point curve

consisting of β-amylase, Apoferritin, and Thyroglobulin. Samples were diluted to 40 nM in PBS.

To each well, 10μL of PBS was added to focus the system before adding 10μL of sample and

mixing for a final concentration of 20 nM. Recorded data for 60s, with the machine counting

individual adsorption events. The DiscoverMP processing software (Refeyn) was used to assign

molecular weights to individual events.

Mouse Immunizations

Immunization in V_H1-$2R^{JH2}$/$V\kappa1$-$33R^{CS\Delta/hTdT}$ (SE13) mice [72] were intramuscularly immunized

with LayV-F_WT (25 mcg/animal) and NiVop8 (25 mcg/animal) adjuvanted with GLA-SE

(IDRI EM-082, 5 mcg/animal) at weeks 0, 4, 15 and 21. Serum titers were monitored by ELISA

as described below. Mice with high-binding antibody titers were selected for the subsequent

spleen cell fusion experiments.

Hybridoma cell line generation and monoclonal antibody production

Mice were boosted with the indicated priming antigen 3 days prior to fusion. Spleen cells were

harvested and fused with NS0 murine myeloma cells using PEG1500 to generate hybridomas [32].

After 2 weeks, supernatant of hybridoma clones were collected and screened by binding ELISA

as described below. Hybridomas that secreted LayV-F reactive antibodies were cloned by

limiting dilution until the phenotypes of all limiting dilution wells were identical. IgG mAbs

were purified by protein G purification.

1003

Indirect binding ELISA method

ELISA assays were utilized for three purposes, measuring mouse serum antibody titers,

screening for antigen specific hybridoma B cell clones, and characterizing the binding of

monoclonal human IgG and mouse IgG. 384 well ELISA plates (Costar #3700) were coated with

2 μg/mL streptavidin (Thermo Fisher Scientific Inc. Cat. No. S-888) or protein antigen in 0.1M

sodium bicarbonate overnight at 4ºC. Plates were washed with PBS/0.1% Tween-20 and blocked

for one hour with assay diluent (PBS containing 4%(w/v) whey protein/15% Normal Goat

Serum/0.5% Tween-20/ 0.05% Sodium Azide). Streptavidin coated plates were washed and

followed by 10 μL Twin-Strep-tag® (IBA Lifesciences GmbH) protein at 2 μg/mL in assay

1013 diluent for one hour. All plates were then washed and samples added in 10µl volumes with
1014 dilution scheme and secondary specifics depending on sample type as follows. Mouse serum was
1015 titrated from 1 to 30 in three-fold steps and incubated for 1 hour. Plates were washed and
1016 followed with 10µL goat anti-mouse IgG-HRP secondary antibody diluted 1:10,000 (Southern
1017 Biotech #1030-05). Hybridoma supernatants were added undiluted as a single well for 1 hour,
1018 washed and followed with 10 µL goat anti-mouse IgG-HRP. Monoclonal mouse IgG and Human
1019 IgG were diluted to 100 µg/mL, titrated in three-fold steps and incubated for 1 hour. Plates were
1020 washed and followed with 10 µL goat anti-Mouse IgG Fab-HRP diluted 1:10,000 (Southern
1021 Biotech 1015-05) for mouse IgGs or 10 µL of goat anti-human IgG Fab-HRP diluted 1:15,000
1022 (Jackson Immunoresearch, 109-035-097) for human IgG monoclonal mAbs. After 1 hour, plates
1023 were washed again and detected with 20 µL SureBlue Reserve (Seracare 5120-0081) for 15
1024 minutes. Reactions were stopped with the addition of 20 µL HCl stop solution. Plates were read
1025 at 450 nm using a Spectramax 384 plus.
1026
1027 **Antibody gene cloning and sequencing**
1028 Cell suspensions of the 22F5 hybridoma cell line were pelleted by centrifugation at 300 g for 5
1029 minutes. The cell pellets were washed twice with Phosphate-buffered saline (PBS, 1X) to
1030 remove residual culture medium. The 22F5 antibody genes were amplified from the hybridoma
1031 cells by RT-PCR. Briefly, RNA was isolated from the cell pellets by adding them to reverse
1032 transcription solution. Immunoglobulin genes were reverse-transcribed using Superscript III
1033 (Thermo Fisher Scientific) with random hexamer oligonucleotides (Gene Link, Hawthorne, NY)
1034 as primers. The cDNA served as a template for nested PCR amplification of the antibody heavy
1035 and light chain genes. The PCR used mouse antibody gene-specific primers [73] and was carried
1036 out with AmpliTaq Gold 360 (Thermo Fisher Scientific). The PCR products were purified using
1037 the Biomek FX Laboratory Automation Workstation (Beckman Coulter, Brea, CA). Purified
1038 PCR products were then sequenced using Sanger sequencing to obtain the antibody gene
1039 sequences. The V(D)J rearrangement, somatic hypermutation frequency, and CDR3
1040 (complementarity-determining region 3) length of the VH (heavy chain variable region) and
1041 VK/L (light chain variable region) genes were analyzed using a custom in-house bioinformatics
1042 pipeline for immunogenetic analysis. Annotation was performed using Partis [74] with a custom
1043 knock-in mouse reference that combined the knocked-in human V_H1-2*02, J_H2*01, and V_K1-
1044 33*01 with mouse endogenous V, D and J gene segments.
1045
1046 **Cryo-EM grid Preparation and Imaging**
1047 To prepare grids, Quantifoil R1.2/1.3 (Cu, 300-mesh; Electron Microscopy Sciences, PA) grids
1048 were glow discharged for 15 seconds at 15 mA using a PELCO easiGlow Cleaning System (Ted
1049 Pella Inc). The final concentration of purified AngV-F, LayV-1-F, and LayV-F-DS ectodomains
1050 was maintained as 1.5 mg/ml in PBS, with a 5x molar ratio of 22F5 for LayV-1-F and 4.87x ratio
1051 for LayV-F-DS. 0.005 % (w/v) of n-dodecyl β-D-maltoside (DDM) was added to the AngV-F
1052 samples and 0.005% (w/v) DDM and 2% glycerol to the LayV-1-F and LayV-F-DS samples

1053   before applying to the grid to prevent the protein from adhering to the air-water interface. 3.0 µL
1054   of the protein sample was applied to the grid and incubated for 30 seconds at >95% humidity.
1055   Excess protein was blotted away for 2.5 seconds before being plunge frozen into liquid ethane
1056   using Leica EM GP2 plunge freezer (Leica Microsystems). Cryo-grids were imaged using either
1057   an FEI Titan Krios (Thermo Scientific) or Tundra cryo TEM (Thermo Scientific).
1058
The Titan Krios TEM was used for the determination of the AngV-F trimer, dimer-of-trimer, and
22F5 Fab-LayV-1-F complex structures. The Krios was equipped with a K3 camera (Gatan) at
81k magnification, operated at 300keV. For AngV-F, approximately 24,000 micrographs were
collected at nominal defocused range between -2.8 to -1.7 µm with a dose range of 63-65 e/A^2.
For LayV-1-F, 9,715 micrographs were collected at a nominal defocused range between -2.8 to -
1.2 µm with a dose range of 58.6-60.6 e/A^2.
1065
The Tundra TEM was used for determination of the AngV-F hexameric lattice and 22F5 Fab-
LayV-F-DS complex structures. For the AngV-F hexameric lattice, the Tundra was equipped
with a CETA-F camera (Thermo Scientific) at 180k magnification, operated at 100keV.
Approximately 4,000 micrographs were collected at nominal defocused range between -3.0 to -
1.5 µm with a dose range of 23-25 e/A^2. For the 22F5 Fab-LayV-F-DS complex, the Tundra was
equipped with a Falcon 4i camera (Thermo Scientific) at 180k magnification, operated at
100keV. 9,514 micrographs were collected at a nominal defocused range between -2.5 to -0.7
µm with a dose of 30.72 e/A^2.
1074
Cryo-EM Data Processing: Cryo-EM image quality was monitored on-the-fly during data
collection using automated processing routines. Data processing was carried out using
cryoSPARC [75,76]. Micrographs were curated through contrast transfer function (CTF) where
greater than >30 Å were discarded. Automated blob picker was used to assign the particle
position. Different box sizes are utilized to accommodate the varying dimensions of specific
molecular assemblies. For instance, monomer particles are extracted using a box size of 320
pixels, while dimer particles require a larger box size of 512 pixels. For even larger molecular
assemblies, such as hexamer lattices, a box size of 1024 pixels was employed. Following particle
extraction, multiple rounds of 2D classification was performed to remove junk. *ab-initio* 3D
reconstruction was used to create 3D reconstructions and poor-quality particles were discarded
after thorough heterogeneous refinement. Final resulting volumes were subjected to non-uniform
refinement to build a high-resolution 3D reconstruction. Phenix [77], Coot [78], Pymol, nextPYP [79]
and ChimeraX [80] were used for model building and refinement. Models 8TVE [20] and 8U1R [30]
were used as startup models for post-fusion and pre-fusion LayV-F model building, respectively.
1089
X-ray crystallography.
Crystals were grown via the vapor diffusion method at room temperature in a siting drop well
format. GakV-2-G head domain protein crystals were formed by mixing 0.20 µL of protein at 15

mg/mL with 0.20 μL of well solution containing 0.2 M magnesium sulfate heptahydrate, 20%
w/v PEG3350 at pH 7.1. Crystals appeared within one week.
Cryoprotection of the crystals was done by mixing glycerol to a final concentration of 50% with
the well solution. Crystals were moved to the drop containing the well solution and glycerol and
soaked for one minute then flash-cooled in liquid nitrogen and data were collected at the NSLS-
II, Beamline 19-ID at 100 K and a wavelength of 1 Å. All data were indexed and integrated using
iMosflm [81] and scaled using AIMLESS. Phaser [82] in the PHENIX suite was used to perform
molecular replacement using a model generated from the AlphaFold3 prediction server [83] using
the GakV-2-G head domain sequence. Phenix refine [84] was used for data refinement, and manual
refinement was done in Coot [78].

1103

References
1   Rima, B. *et al.* ICTV Virus Taxonomy Profile: Paramyxoviridae. *J Gen Virol* **100**, 1593-
1594 (2019). https://doi.org/10.1099/jgv.0.001328
2   Chua, K. B. *et al.* Nipah Virus: A Recently Emergent Deadly Paramyxovirus. *Science*
288, 1432-1435 (2000). https://doi.org/doi:10.1126/science.288.5470.1432
3   Murray, K. *et al.* A Morbillivirus that Caused Fatal Fisease in Horses and Humans.
Science **268**, 94-97 (1995). https://doi.org/doi:10.1126/science.7701348
4   Murray, K. *et al.* in *Emerging Infections 1*   43-58 (1997).
5   Zhang, X.-A. *et al.* A Zoonotic Henipavirus in Febrile Patients in China. *New England*
Journal of Medicine **387**, 470-472 (2022). https://doi.org/10.1056/NEJMc2202705
6   Lee, S.-H. *et al.* Discovery and Genetic Characterization of Novel Paramyxoviruses
Related to the Genus Henipavirus in Crocidura Species in the Republic of Korea. *Viruses*
13, 2020 (2021).
7   Vanmechelen, B. *et al.* The characterization of multiple novel paramyxoviruses
highlights the diverse nature of the subfamily Orthoparamyxovirinae. *Virus Evolution* **8**
(2022). https://doi.org/10.1093/ve/veac061
8   Horemans, M., Van Bets, J., Joly Maes, T., Maes, P. & Vanmechelen, B. Discovery
and genome characterization of six new orthoparamyxoviruses in small Belgian
mammals. *Virus Evolution* **9** (2023). https://doi.org/10.1093/ve/vead065
9   Zhang, J. T. *et al.* Decoding the RNA viromes in shrew lungs along the eastern coast of
China. *NPJ Biofilms Microbiomes* **10**, 68 (2024). https://doi.org/10.1038/s41522-024-
00543-3
10   Simmonds, P. *et al.* Changes to virus taxonomy and the ICTV Statutes ratified by the
International Committee on Taxonomy of Viruses (2024). *Arch Virol* **169**, 236 (2024).
https://doi.org/10.1007/s00705-024-06143-y
11   White, J. M., Delos, S. E., Brecher, M. & Schornberg, K. Structures and mechanisms of
viral membrane fusion proteins: multiple variations on a common theme. *Crit Rev*
Biochem Mol Biol **43**, 189-219 (2008). https://doi.org/10.1080/10409230802058320
12   Iorio, R. M., Melanson, V. R. & Mahon, P. J. Glycoprotein interactions in paramyxovirus
fusion. *Future Virol* **4**, 335-351 (2009). https://doi.org/10.2217/fvl.09.17
13   May, A. J. & Acharya, P. Structural Studies of Henipavirus Glycoproteins. *Viruses* **16**,
195 (2024).
14   Wang, Z. *et al.* Architecture and antigenicity of the Nipah virus attachment glycoprotein.
Science **375**, 1373-1378 (2022). https://doi.org/doi:10.1126/science.abm5561

1138	15	Dang, H. V. *et al.* Broadly neutralizing antibody cocktails targeting Nipah virus and
1139		Hendra virus fusion glycoproteins. *Nature Structural & Molecular Biology* **28**, 426-
1140		434 (2021). https://doi.org/10.1038/s41594-021-00584-8
1141	16	Dong, J. *et al.* Potent Henipavirus Neutralization by Antibodies Recognizing Diverse
1142		Sites on Hendra and Nipah Virus Receptor Binding Protein. *Cell* **183**, 1536-1550.e1517
1143		(2020). https://doi.org/https://doi.org/10.1016/j.cell.2020.11.023
1144	17	Avanzato, V. A. *et al.* A structural basis for antibody-mediated neutralization of Nipah
1145		virus reveals a site of vulnerability at the fusion glycoprotein apex. *Proceedings of the*
1146		*National Academy of Sciences* **116**, 25057-25067 (2019).
1147		https://doi.org/10.1073/pnas.1912503116
1148	18	Dang, H. V. *et al.* An antibody against the F glycoprotein inhibits Nipah and Hendra
1149		virus infections. *Nature Structural & Molecular Biology* **26**, 980-987 (2019).
1150		https://doi.org/10.1038/s41594-019-0308-9
1151	19	May, A. J., Pothula, K. R., Janowska, K. & Acharya, P. Structures of Langya Virus
1152		Fusion Protein Ectodomain in Pre- and Postfusion Conformation. *J Virol* **97**, e0043323
1153		(2023). https://doi.org/10.1128/jvi.00433-23
1154	20	Wang, Z. *et al.* Structure and design of Langya virus glycoprotein antigens. *Proceedings*
1155		*of the National Academy of Sciences* **121**, e2314990121 (2024).
1156		https://doi.org/doi:10.1073/pnas.2314990121
1157	21	Camacho, C. *et al.* BLAST+: architecture and applications. *BMC Bioinformatics* **10**, 421
1158		(2009). https://doi.org/10.1186/1471-2105-10-421
1159	22	Lo, M. K. *et al.* Determination of the henipavirus phosphoprotein gene mRNA editing
1160		frequencies and detection of the C, V and W proteins of Nipah virus in virus-infected
1161		cells. *J Gen Virol* **90**, 398-404 (2009). https://doi.org/10.1099/vir.0.007294-0
1162	23	Wang, L.-F. *et al.* Molecular biology of Hendra and Nipah viruses. *Microbes and*
1163		*Infection* **3**, 279-287 (2001). https://doi.org/https://doi.org/10.1016/S1286-
1164		4579(01)01381-8
1165	24	Sievers, F. *et al.* Fast, scalable generation of high-quality protein multiple sequence
1166		alignments using Clustal Omega. *Mol Syst Biol* **7**, 539 (2011).
1167	25	Xu, K. *et al.* Crystal Structure of the Hendra Virus Attachment G Glycoprotein Bound to
1168		a Potent Cross-Reactive Neutralizing Human Monoclonal Antibody. *PLOS Pathogens* **9**,
1169		e1003684 (2013). https://doi.org/10.1371/journal.ppat.1003684
1170	26	Fan, P. *et al.* A potent Henipavirus cross-neutralizing antibody reveals a dynamic fusion-
1171		triggering pattern of the G-tetramer. *Nat Commun* **15**, 4330 (2024).
1172		https://doi.org/10.1038/s41467-024-48601-w
1173	27	Guo, Y. *et al.* The cryo-EM structure of homotetrameric attachment glycoprotein from
1174		langya henipavirus. *Nature Communications* **15**, 812 (2024).
1175		https://doi.org/10.1038/s41467-024-45202-5
1176	28	Meier, S., Güthe, S., Kiefhaber, T. & Grzesiek, S. Foldon, the natural trimerization
1177		domain of T4 fibritin, dissociates into a monomeric A-state form containing a stable beta-
1178		hairpin: atomic details of trimer dissociation and local beta-hairpin stability from residual
1179		dipolar couplings. *J Mol Biol* **344**, 1051-1069 (2004).
1180		https://doi.org/10.1016/j.jmb.2004.09.079
1181	29	Sibert, B. S. *et al.* Assembly of respiratory syncytial virus matrix protein lattice and its
1182		coordination with fusion glycoprotein trimers. *Nature Communications* **15**, 5923 (2024).
1183		https://doi.org/10.1038/s41467-024-50162-x

1184   30   Byrne, P. O. *et al.* Prefusion stabilization of the Hendra and Langya virus F proteins. *J*
1185   *Virol* **98**, e0137223 (2024). https://doi.org/10.1128/jvi.01372-23
1186   31   Loomis, R. J. *et al.* Structure-Based Design of Nipah Virus Vaccines: A Generalizable
1187   Approach to Paramyxovirus Immunogen Development. *Frontiers in Immunology* **11**
1188   (2020). https://doi.org/10.3389/fimmu.2020.00842
1189   32   Haynes, B. F., Eisenbarth, G. S. & Fauci, A. S. Human lymphocyte antigens: production
1190   of a monoclonal antibody that defines functional thymus-derived lymphocyte subsets.
1191   *Proc Natl Acad Sci U S A* **76**, 5829-5833 (1979). https://doi.org/10.1073/pnas.76.11.5829
1192   33   Byrne, P. O. *et al.* Structural basis for antibody recognition of vulnerable epitopes on
1193   Nipah virus F protein. *Nature Communications* **14**, 1494 (2023).
1194   https://doi.org/10.1038/s41467-023-36995-y
1195   34   Scanlan, C. N. *et al.* The broadly neutralizing anti-human immunodeficiency virus type 1
1196   antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of
1197   gp120. *J Virol* **76**, 7306-7321 (2002). https://doi.org/10.1128/jvi.76.14.7306-7321.2002
1198   35   Lee, C. D. *et al.* A cross-neutralizing antibody between HIV-1 and influenza virus. *PLoS*
1199   *Pathog* **17**, e1009407 (2021). https://doi.org/10.1371/journal.ppat.1009407
1200   36   Williams, W. B. *et al.* Fab-dimerized glycan-reactive antibodies are a structural category
1201   of natural antibodies. *Cell* **184**, 2955-2972.e2925 (2021).
1202   https://doi.org/10.1016/j.cell.2021.04.042
1203   37   Ziółkowska, N. E. *et al.* Domain-swapped structure of the potent antiviral protein
1204   griffithsin and its mode of carbohydrate binding. *Structure* **14**, 1127-1135 (2006).
1205   https://doi.org/10.1016/j.str.2006.05.017
1206   38   Sun, J. *et al.* C3-Symmetric Aromatic Core of Griffithsin Is Essential for Potent Anti-
1207   HIV Activity. *ACS Chemical Biology* **17**, 1450-1459 (2022).
1208   https://doi.org/10.1021/acschembio.1c00990
1209   39   Lo, M. K. *et al.* Griffithsin Inhibits Nipah Virus Entry and Fusion and Can Protect Syrian
1210   Golden Hamsters From Lethal Nipah Virus Challenge. *J Infect Dis* **221**, S480-s492
1211   (2020). https://doi.org/10.1093/infdis/jiz630
1212   40   Marcink, T. C. *et al.* Subnanometer structure of an enveloped virus fusion complex on
1213   viral surface reveals new entry mechanisms. *Science Advances* **9**, eade2727 (2023).
1214   https://doi.org/doi:10.1126/sciadv.ade2727
1215   41   Xu, K. *et al.* Crystal Structure of the Pre-fusion Nipah Virus Fusion Glycoprotein
1216   Reveals a Novel Hexamer-of-Trimers Assembly. *PLOS Pathogens* **11**, e1005322 (2015).
1217   https://doi.org/10.1371/journal.ppat.1005322
1218   42   Isaacs, A. *et al.* Structure and antigenicity of divergent Henipavirus fusion glycoproteins.
1219   *Nature Communications* **14**, 3577 (2023). https://doi.org/10.1038/s41467-023-39278-8
1220   43   Barash, S., Wang, W. & Shi, Y. Human secretory signal peptide description by hidden
1221   Markov model and generation of a strong artificial signal peptide for secreted protein
1222   expression. *Biochem Biophys Res Commun* **294**, 835-842 (2002).
1223   https://doi.org/10.1016/s0006-291x(02)00566-1
1224   44   Cheliout Da Silva, S. *et al.* Functional Analysis of the Fusion and Attachment
1225   Glycoproteins of Mojiang Henipavirus. *Viruses* **13** (2021).
1226   https://doi.org/10.3390/v13030517
1227   45   Wang, Z. *et al.* Potent monoclonal antibody-mediated neutralization of a divergent
1228   Hendra virus variant. *Proc Natl Acad Sci U S A* **119**, e2122769119 (2022).
1229   https://doi.org/10.1073/pnas.2122769119

46 Zhang, Q. E. *et al.* SARS-CoV-2 Omicron XBB lineage spike structures, conformations,
antigenicity, and receptor recognition. *Mol Cell* **84**, 2747-2764.e2747 (2024).
https://doi.org/10.1016/j.molcel.2024.06.028
47 Stalls, V. *et al.* Cryo-EM structures of SARS-CoV-2 Omicron BA.2 spike. *Cell Rep* **39**,
111009 (2022). https://doi.org/10.1016/j.celrep.2022.111009
48 Gobeil, S. M. *et al.* Structural diversity of the SARS-CoV-2 Omicron spike. *Mol Cell* **82**,
2050-2068.e2056 (2022). https://doi.org/10.1016/j.molcel.2022.03.028
49 Ke, Z. *et al.* Promotion of virus assembly and organization by the measles virus matrix
protein. *Nature Communications* **9**, 1736 (2018). https://doi.org/10.1038/s41467-018-
04058-2
50 Wong, J. J. W. *et al.* Monomeric ephrinB2 binding induces allosteric changes in Nipah
virus G that precede its full activation. *Nature Communications* **8**, 781 (2017).
https://doi.org/10.1038/s41467-017-00863-3
51 Bowden, T. A. *et al.* Structural basis of Nipah and Hendra virus attachment to their cell-
surface receptor ephrin-B2. *Nature Structural & Molecular Biology* **15**, 567-572 (2008).
https://doi.org/10.1038/nsmb.1435
52 Yuan, P. *et al.* Structural Studies of the Parainfluenza Virus 5 Hemagglutinin-
Neuraminidase Tetramer in Complex with Its Receptor, Sialyllactose. *Structure* **13**, 803-
815 (2005). https://doi.org/https://doi.org/10.1016/j.str.2005.02.019
53 Hashiguchi, T. *et al.* Structure of the measles virus hemagglutinin bound to its cellular
receptor SLAM. *Nature Structural & Molecular Biology* **18**, 135-141 (2011).
https://doi.org/10.1038/nsmb.1969
54 Korber, B. *et al.* Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G
Increases Infectivity of the COVID-19 Virus. *Cell* **182**, 812-827.e819 (2020).
https://doi.org/10.1016/j.cell.2020.06.043
55 Parsons, R. J. & Acharya, P. Evolution of the SARS-CoV-2 Omicron spike. *Cell Rep* **42**,
113444 (2023). https://doi.org/10.1016/j.celrep.2023.113444
56 Rissanen, I. *et al.* Idiosyncratic Mòjiāng virus attachment glycoprotein directs a host-cell
entry pathway distinct from genetically related henipaviruses. *Nature Communications* **8**,
16060 (2017). https://doi.org/10.1038/ncomms16060
57 Whitmer, S. L. M. *et al.* Inference of Nipah virus evolution, 1999-2015. *Virus Evol* **7**,
veaa062 (2021). https://doi.org/10.1093/ve/veaa062
58 Cortes-Azuero, O. *et al.* The Genetic Diversity of Nipah Virus Across Spatial Scales. *J
Infect Dis* **230**, e1235-e1244 (2024). https://doi.org/10.1093/infdis/jiae221
59 Gaudino, M. *et al.* High Pathogenicity of Nipah Virus from Pteropus lylei Fruit Bats,
Cambodia. *Emerg Infect Dis* **26**, 104-113 (2020). https://doi.org/10.3201/eid2601.191284
60 Wang, J. *et al.* A new Hendra virus genotype found in Australian flying foxes. *Virol J* **18**,
197 (2021). https://doi.org/10.1186/s12985-021-01652-7
61 Marsh, G. A. *et al.* Cedar virus: a novel Henipavirus isolated from Australian bats. *PLoS
Pathog* **8**, e1002836 (2012). https://doi.org/10.1371/journal.ppat.1002836
62 Drexler, J. F. *et al.* Bats host major mammalian paramyxoviruses. *Nat Commun* **3**, 796
(2012). https://doi.org/10.1038/ncomms1796
63 Madera, S. *et al.* Discovery and Genomic Characterization of a Novel Henipavirus,
Angavokely Virus, from Fruit Bats in Madagascar. *Journal of Virology* **96**, e00921-
00922 (2022). https://doi.org/doi:10.1128/jvi.00921-22

64 Pernet, O., Beaty, S. & Lee, B. Functional rectification of the newly described African
henipavirus fusion glycoprotein (Gh-M74a). *J Virol* **88**, 5171-5176 (2014).
https://doi.org/10.1128/jvi.03655-13
65 Wu, Z. *et al.* Novel Henipa-like virus, Mojiang Paramyxovirus, in rats, China, 2012.
Emerg Infect Dis **20**, 1064-1066 (2014). https://doi.org/10.3201/eid2006.131022
66 Camacho, C. *et al.* BLAST+: architecture and applications. *BMC Bioinformatics* **10**, 421
(2009). https://doi.org/10.1186/1471-2105-10-421
67 Katoh, K., Misawa, K., Kuma, K. & Miyata, T. MAFFT: a novel method for rapid
multiple sequence alignment based on fast Fourier transform. *Nucleic Acids Res* **30**,
3059-3066 (2002). https://doi.org/10.1093/nar/gkf436
68 Bianchini, G. & Sánchez-Baracaldo, P. TreeViewer: Flexible, modular software to
visualise and manipulate phylogenetic trees. *Ecology and Evolution* **14**, e10873 (2024).
https://doi.org/https://doi.org/10.1002/ece3.10873
69 Whittle, J. R. *et al.* Broadly neutralizing human antibody that recognizes the receptor-
binding pocket of influenza virus hemagglutinin. *Proc Natl Acad Sci U S A* **108**, 14216-
14221 (2011). https://doi.org/10.1073/pnas.1111497108
70 Lee, J. *et al.* A broadly generalizable stabilization strategy for sarbecovirus fusion
machinery vaccines. *Nature Communications* **15**, 5496 (2024).
https://doi.org/10.1038/s41467-024-49656-5
71 Zivanov, J. *et al.* New tools for automated high-resolution cryo-EM structure
determination in RELION-3. *Elife* **7** (2018). https://doi.org/10.7554/eLife.42166
72 Luo, S. *et al.* Humanized V(D)J-rearranging and TdT-expressing mouse vaccine models
with physiological HIV-1 broadly neutralizing antibody precursors. *Proceedings of the*
National Academy of Sciences **120**, e2217883120 (2023).
https://doi.org/doi:10.1073/pnas.2217883120
73 Tiller, T., Busse, C. E. & Wardemann, H. Cloning and expression of murine Ig genes
from single B cells. *Journal of Immunological Methods* **350**, 183-193 (2009).
https://doi.org/https://doi.org/10.1016/j.jim.2009.08.009
74 Ralph, D. K. & Matsen, F. A. t. Consistency of VDJ Rearrangement and Substitution
Parameters Enables Accurate B Cell Receptor Sequence Annotation. *PLoS Comput Biol*
12, e1004409 (2016). https://doi.org/10.1371/journal.pcbi.1004409
75 Punjani, A., Zhang, H. & Fleet, D. J. Non-uniform refinement: adaptive regularization
improves single-particle cryo-EM reconstruction. *Nature Methods* **17**, 1214-1221 (2020).
https://doi.org/10.1038/s41592-020-00990-8
76 Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for
rapid unsupervised cryo-EM structure determination. *Nature Methods* **14**, 290-296
(2017). https://doi.org/10.1038/nmeth.4169
77 Liebschner, D. *et al.* Macromolecular structure determination using X-rays, neutrons and
electrons: recent developments in Phenix. *Acta Crystallographica Section D* **75**, 861-877
(2019). https://doi.org/doi:10.1107/S2059798319011471
78 Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. *Acta*
Crystallogr D Biol Crystallogr **60**, 2126-2132 (2004).
https://doi.org/10.1107/s0907444904019158
79 Liu, H.-F. *et al.* nextPYP: a comprehensive and scalable platform for characterizing
protein variability in situ using single-particle cryo-electron tomography. *Nature Methods*
20, 1909-1919 (2023). https://doi.org/10.1038/s41592-023-02045-0

80   Meng, E. C. *et al.* UCSF ChimeraX: Tools for structure building and analysis. *Protein Sci*
1322   **32**, e4792 (2023). https://doi.org/10.1002/pro.4792
1323   81   Battye, T. G. G., Kontogiannis, L., Johnson, O., Powell, H. R. & Leslie, A. G. W.
1324   iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM.
1325   *Acta Crystallographica Section D* **67**, 271-281 (2011).
1326   https://doi.org/doi:10.1107/S0907444910048675
1327   82   McCoy, A. J. *et al.* Phaser crystallographic software. *Journal of Applied Crystallography*
1328   **40**, 658-674 (2007). https://doi.org/doi:10.1107/S0021889807021206
1329   83   Abramson, J. *et al.* Accurate structure prediction of biomolecular interactions with
1330   AlphaFold 3. *Nature* **630**, 493-500 (2024). https://doi.org/10.1038/s41586-024-07487-w
1331   84   Adams, P. D. *et al.* PHENIX: a comprehensive Python-based system for macromolecular
1332   structure solution. *Acta Crystallogr D Biol Crystallogr* **66**, 213-221 (2010).
1333   https://doi.org/10.1107/s0907444909052925
1334
1335

Figure 1: Selection and Classification of Henipavirus Species. Upper Left: A flowchart that describes the origin of sequences used and the filtering mechanisms, genome and F/G sequence completion, used to assemble a list of non-redundant F and G proteins. **Tree:** A phylogenetic tree based on full-genome nucleotide sequences of the selected strains. Horizontal branch lengths are to scale to represent sequence divergence. Hollow boxes are drawn to represent broad groupings within the tree such as genus, with Classical/Bat Henipaviruses (green) and Shrew/Parahenipaviruses (orange), as well as potential species groupings such as Nipah viruses, (dark red) and Hendra viruses (dark blue). Solid highlight boxes are drawn to represent more narrow groupings of specific species or subspecies groupings such as Nipah-Malaysia (yellow), Nipah-Bangladesh (purple), and Langya-China (tan). The tips of each branch are labelled with the strain names and associated gen bank accession number. Each tip is colored based on which unique glycoproteins are available from that strain: unique F ectodomain only, blue, unique G ectodomain only, yellow, no unique G head domain, dashed red border, both unique F and G ectodomain, green.

Figure 2: Purification and Antigenic Characterization of Henipavirus Fusion Proteins. (A) Representative SEC profiles of HNV-F Proteins with peaks annotated. The oligomer-of-trimer peak, sometimes called the "middle peak," and the main trimer peaks are collected separately. NiVop08 is a pre-fusion stabilized construct [31] not part of the panel but purified for a vaccination study and for comparison to wild-type proteins. An inset to the right shows mass photometry analysis of NiV-M1-F SEC components. Each individual measurement is assigned a calculated molecular weight by the instrument software, and individual results are binned in 10 kDa bin sizes. The graph reports the count of events for each molecular weight bin with the main, middle, and mixed peak data overlayed. **(B)** Graphical timeline of a vaccination study in mice using HNV-F antigens. Each group was vaccinated with LayV-C1-F and boosted with LayV-C1-F or NiV antigens as marked. Blood draws and antigen injections occurred at the indicated weeks after the start of the study. The weeks with an asterisk, with the syringe and blood drop marked with F are weeks where a fusion was performed on an individual mouse. **(C)** Heatmap of antibody binding to HNV-F proteins, on a spectrum of blue for low binding to red for high binding. The left-side graph is based on ELISA data with immobilized F proteins, antibody analytes, and anti-Human Fab-conjugated HRP as a reporter. The values for each combination are based on the log of the area under the curve for the plotted absorbance over increasing concentrations. The right-side graph is based on Bio-layer interferometry (BLI) with immobilized F proteins and direct measurement of analyte to the BLI sensors, either mouse Fabs or mouse IgG (22F5 and 1C8). The values for each combination are based on the maximum wavelength shift measured during the association phase of the BLI experiment. HNV-F antigens colored as in Figure 1, antibody analytes colored as follows: green, known anti-NiV-F binding; salmon, known anti-LayV-F binding; gray, anti-influenza HA negative control antibody (ELISA only). **(D)** Surface plasmonic resonance (SPR) analysis of 22F5 and 4G5 antibody competition for binding of a series of LayV-F constructs in a variety of conformational states. Solid lines represent 22F5 alone and dashed lines with 4G5.

Figure 3: Structure and Binding Kinetics of 22F5 Fab with LayV-F Ectodomain. A-B. Cryo-EM maps of 22F5 Fab bound to post-fusion LayV-1-F (**A**) or pre-fusion LayV-F-DS (**B**) with domains colored and labelled. **C.** Views of the models (Left: Post-Fusion, Right: Pre-Fusion) built from the Cryo-EM maps in cartoon representation and colored by domain or CDR. **D.** Polar contacts between 22F5 Fab and the post-fusion LayV-1-F. Interacting residues labeled and shown in stick representation, with the color scheme continued from C. **E.** Measurement of affinity and kinetics of binding of 22F5 Fab to LayV-F ectodomains. The black lines in the graphs are the blank subtracted sensorgrams and the red lines are the fit of the data to a 1:1 Langmuir binding model. The table to the right shows the affinity and kinetic parameters obtained from the measurements.

Figure 4: Thermostability of Henipavirus F Proteins. **(A)** DSF profiles of a set of HNV proteins showing the first derivative of 350/330nm emission ratio as a function of temperature. Dotted lines of the same color represent the DSF profile of the same proteins after being incubated at 60°C for 90 minutes. **(B)** Two-dimensional NSEM class averages of a portion of the heat-treated samples from A. **(C)** DSF profiles of diverse HNV-F species. Sections of the profile are noted, indicating the conformational steps occurring at those temperatures, with highlighting of peaks of interest. **(D)** A subset of DSF profiles from C, containing only those species that do not demonstrate any noticeable conformational conversion peak. Below are representative two-dimensional NSEM class averages for select members of this subset. **(E)** A subset of DSF profiles from C, containing only those species that demonstrate some presence of the standard conformational conversion signal. Below are representative two-dimensional NSEM class averages for select members of this subset. **(F)** A subset of DSF profiles from C, containing only those species that demonstrate a profile notably different from the typical HNV-F species. Below are representative two-dimensional NSEM class averages for the two members of this subset.

Figure 5. Cryo-EM Structure of the AngV-F Ectodomain. (A) Three different particle populations in the AngV-F and their representative 2D classes. Cryo-EM reconstruction of top and side view shown for AngV F trimer (left), dimer-of-trimers (middle) and hexameric lattice (right). **(B)** Comparison of the AngV-F, LayV-F and NiV-F proteins. Top. A slice through the F-protein visualizing the central cavity and the placement of the stalk region within the F-protein. Bottom. A top-down view showing measurements. **(C)** Zoom-in view of the stalk region featuring amino acid present at the start of helix bundle (top) and the electrostatics of the region (bottom), with sequence alignment at the local region between each of the three species below. The HRB start residue is marked red in the sequence alignment. **(D)** AngV-F cryo-EM structure colored by protomer with the glycans shown as spheres and colored by element. Glycans at the different regions (Apex, non-canonical NNV, stalk) are marked with arrows. **(E)** The dimer-of-trimer interaction interface is shown in surface representation (top), along with their molecular-level interactions and zoomed-in views showing details of the interface contacts (bottom).

A HRB Proline Mutation

	NiV Residue Number																				
	443	444	445	446	447	448	449	450	451	452	453	454	455	456	457	458	459	460	461	462	463
NiV-M1-F	I	A	I	G	P	P	V	F	T	D	P	V	D	I	S	S	Q	I	S	S	M
SHNV5-1-F	I	T	L	G	P	P	I	V	I	D	P	I	D	I	G	N	Q	L	A	G	I
GakV-1-F	I	E	L	G	P	P	I	V	I	D	P	I	D	L	G	G	Q	I	A	G	I

Figure 6: Translatable Pre-fusion Stabilization of Henipavirus F Proteins. (A) Location of HRB proline mutation in select HNV-F proteins. Left: Site of NiV K453P mutation shown as red spheres in the HNV-F ectodomain structure, with protomers colored in shades of blue. Right: A sequence alignment of the residues surrounding the HRB proline mutation, colored by residue type: hydrophobic, orange, polar, pink, negative charge, red, aromatic, white, conformationally significant, green, HRB proline mutation, dark green. **(B-D)** Characterization of the HRB proline mutation in three HNV-F species, **(B)** NiV-M1-F, **(C)** SHNV5-1-F, **(D)** GakV-1-F. Top: SEC overlay of the WT (right axis) and mutant (left axis) with mAU values scaled to a 1L transfection volume. Middle: DSF analysis overlay of the WT and mutant. The middle line represents the average with standard deviation represented with thin lines above and below the average line and shaded in-between. Bottom: Comparison of representative NSEM 2D classes from WT (top) and mutant (Bottom).

Figure 7: Structure and Characterization of Henipavirus G Proteins. (A) Heatmap of recombinant Fc-Ephrin-B2 and B3 binding to G head domains, on a spectrum of blue for low binding to red for high binding. The graph is based on BLI data with immobilized Ephrin and G head domain analytes. The value for each combination is based on the maximum response value from the association step. G head domain antigens in the table colored by group as in Figure 1. **(B)** Heatmap of antibody binding to G head domains, with color scheme identical to (A). The graph is based on BLI data as described in (A) using immobilized anti-G antibodies. **(C)** Sequence alignment of the C terminal end of select HNV-G proteins. **(D)** Three views of the GakV-G head domain colored in rainbow from N to C terminal. **(E)** Superposition of GakV-G head domain on Ephrin-bound NiV-G head domain (PDB: 2VSM [51]). GakV-G is colored gray, NiV-G cyan and Ephrin light blue. Ephrin is shown as a transparent surface. The GakV-G glycan 506 is shown as blue spheres. **(F)** Topology diagram of GakV-G protein with blades of the beta propellor colored in rainbow from blade 1 through 6. **(G)** Left: Two views of the GakV-G head domain colored in rainbow with the N terminal Asp to His218 shown as a transparent surface. The additional minidomain defined in the GakV-2-G head structure is highlighted within a dashed oval. Right: G head domains of LayV and NiV.